CRISPR/Cas9-mediated interrogation of a sense-antisense pair involved in the DNA damage response by Goyal, Ashish
  
Dissertation 
 
submitted to the 
Combined Faculties for the Natural Sciences and for Mathematics 
of the Ruperto-Carola University of Heidelberg, Germany 
for the degree of 
Doctor of Natural Sciences 
 
 
 
 
 
 
 
 
 
Presented by 
Ashish Goyal, MSc. 
born in: Jaipur, India 
Oral-examination: 5th May 2017  
  
  
 
 
 
CRISPR/Cas9-mediated interrogation of a sense-antisense 
pair involved in the DNA damage response 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees:  Prof. Dr. Christine Clayton 
 Prof. Dr. Sven Diederichs
Summary 
Previously, the Diederichs lab identified the long non-coding RNA NOP14-AS1 to be induced in A549 and 
HepG2 cells treated with the DNA-damaging drugs Etoposide, Cisplatin, and Bleomycin. Preliminary data 
indicated that NOP14-AS1 was inversely co-regulated with its antisense protein-coding gene NOP14. In this 
study, NOP14-AS1 regulation in DNA damage was further characterized. NOP14-AS1 was consistently induced 
in several cell lines upon treatment with various DNA damaging agents. NOP14-AS1 induction was a p53-
dependent transcriptional response. The DNA damage-induced inverse co-regulation between NOP14 and 
NOP14-AS1 was further confirmed in multiple cell lines using time-course expression analysis upon treatment 
with multiple DNA-damaging agents. NOP14 repression upon DNA damage was p53-dependent and 
preliminary experiments performed indicated its involvement in the p53 pathway and a role in regulating cell 
proliferation. 
Antisense lncRNAs often regulate the expression of their overlapping sense protein-coding genes through 
transcript- as well as transcription-dependent mechanisms. Therefore, it was proposed that NOP14-AS1 
induction could lead to NOP14 repression in cis. The transcript-dependent effects of NOP14-AS1 could be 
uncovered using an RNA interference-/ antisense oligo-based loss-of-function approach. However to uncover 
any transcription-dependent effects, a CRISPR/Cas9-based knockdown (CRISPRi) and overexpression (CRISPRa) 
system for NOP14-AS1 was established. While establishing this system, a major limitation of the CRISPR/Cas9 
system for lncRNA knockdown was discovered and experimentally demonstrated for multiple examples. 
CRISPR/Cas9 targeting of a lncRNA arising from a complex locus can unintentionally affect the expression of its 
neighboring genes advocating for caution while using these systems for knockdown. However, these systems 
were determined to be safe to study the impact of NOP14-AS1 on NOP14 expression.  
NOP14 knockdown using siRNAs had no impact on NOP14-AS1 expression. On the other hand, NOP14 
transcriptional repression using CRISPRi resulted in a NOP14-AS1 induction which could not be reversed by an 
ectopic rescue of NOP14 expression, indicating that this was due to a reduced transcriptional interference. 
However, the NOP14-AS1 induction observed upon CRISPRi knockdown of NOP14 could not account for the 
much stronger NOP14-AS1 induction observed upon DNA damage, indicating that an independent mechanism 
was responsible for the latter. NOP14-AS1 knockdown using antisense oligos / CRISPRi did not have any impact 
on the NOP14 expression. The DNA damage-induced NOP14 repression could not be reversed upon NOP14-
AS1 knockdown. Also, a CRISPRa-mediated NOP14-AS1 induction did not affect NOP14 expression. Together 
these data indicated that neither the NOP14-AS1 transcript nor its transcription could regulate NOP14 
expression. In summary, this study concludes that NOP14-AS1 and NOP14 are independently regulated upon 
DNA damage. However, the role of NOP14-AS1 in DNA damage remains to be established. 
  
  
Zusammenfassung 
Die lange nicht-kodierende RNA (lncRNA) NOP14-AS1, wurde vom Diederichs lab als eine durch Etoposid, 
Cisplatin und Bleomycin (DNA schädigende Mittel) induzierbare lncRNA in A549 und HepG2 Zellen identifiziert. 
Vorläufige Daten zeigten, dass NOP14-AS1 invers ko-reguliert wird mit seinem Antisense-Protein-kodierenden 
Gen NOP14. In dieser Studie wurde die NOP14-AS1-Regulation bei induzierter DNA-Schädigung weiter 
charakterisiert. NOP14-AS1 konnte in mehreren Zelllinien bei Behandlung mit verschiedenen DNA-
schädigenden Mitteln reproduzierbar induziert werden. Die Induktion von NOP14-AS1 wurde von p53 
vermittelt. Die DNA-schädigungsinduzierte inverse Ko-Regulation zwischen NOP14 und NOP14-AS1 wurde in 
mehreren Zelllinien unter Verwendung von Zeitverlaufsexpressionsanalysen bei gleichzeitiger Behandlung mit 
verschiedenen DNA-schädigenden Mitteln weiter bestätigt. Die transkriptionelle Repression von NOP14 nach 
DNA-Schädigung war p53-abhängig, und vorläufige Experimente zeigten die Beteiligung von NOP14-AS1 an der 
p53-Signalkaskade und eine Rolle bei der Regulierung der Zellproliferation. 
Antisense-lncRNAs regulieren häufig die Expression ihrer überlappenden sense-Protein-kodierenden Gene 
durch Transkript- sowie Transkriptions-abhängige Mechanismen. Daher wurde vermutet, dass die NOP14-AS1-
Induktion zu einer NOP14-Repression in cis führen könnte. Die Transkript-abhängigen Effekte von NOP14-AS1 
konnten unter Verwendung eines RNA-Interferenz- / Antisense-Oligo-basierten Funktionsverlust-Ansatzes 
aufgedeckt werden. Um die transkriptionsabhängigen Effekte untersuchen zu können, wurde ein CRISPR / 
Cas9-basiertes Knockdown- (CRISPRi) und Überexpressions- (CRISPRa) -System für NOP14-AS1 etabliert. 
Während der Etablierung von CRISPRi wurde festgestellt, dass die Beeinflussung der Expression einer lncRNA 
in einem komplexen Locus unbeabsichtigte Effekte auslösen kann. So wurde an mehreren Beispielen gezeigt, 
dass die Expression der benachbarten Gene durch CRISPRi ebenfalls beeinflusst wurde. Daher sollte man bei 
der Nutzung von CRISPR / Cas9 zur Modulation der Expression von lncRNAs prinzipiell vorsichtig sein, 
insbesondere bei CRISPRi. In dieser Studie wurde die Verwendung von CRISPRi/a jedoch  als geeignet 
befunden, um die Auswirkungen von NOP14-AS1 auf die NOP14-Expression zu untersuchen. 
Der Knockdown von NOP14 mittels siRNA hatte keinen Einfluss auf die NOP14-AS1-Expression. Bei der 
Verwendung von CRISPRi zum Knockdwon von NOP14, zeigte sich jedoch eine NOP14-AS1-Induktion. Die 
Induktion von NOP14-AS1 konnte auch mittels ektopischer NOP14-Expression nicht rückgängig gemacht 
werden, was als Ursache einen transkriptionellen Interferenz Mechanismus nahe legt. Allerdings konnte die 
NOP14-AS1-Induktion, die beim CRISPRi-Knockdown von NOP14 beobachtet wurde, nicht für die viel stärkere 
NOP14-AS1-Induktion verantwortlich sein, die bei der Benutzung von DNA-schädigenden Mitteln auftrat. Der 
Knockdown von NOP14-AS1 mittels Antisense-Oligos / CRISPRi, hatte keine Auswirkung auf die NOP14-
Expression. Auch die durch DNA-schädigende Mittel verusachte NOP14–Repression konnte durch einen 
NOP14-AS1-Knockdown nicht rückgängig gemacht werden. Weiterhin hatte die CRISPRa-vermittelte NOP14-
AS1-Induktion keinen Einfluss auf die NOP14-Expression. Die Gesamtschau der Daten zeigt, dass weder das 
NOP14-AS1-Transkript noch seine Transkription die NOP14-Expression regulieren können. Zusammenfassend 
kommt diese Studie zu dem Schluss, dass NOP14-AS1 und NOP14 im Falle von auftretender DNA-Schädigung 
unabhängig voneinander reguliert sind. Die Rolle von NOP14-AS1 bei der zellulären Antwort auf DNA-Schäden 
muss noch weiter geklärt werden.  
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1. Introduction 
1.1. Long Non-Coding RNAs 
1.1.1. Discovery and Definition 
In 1956, in an early draft of his later published article “Ideas on protein synthesis”, Francis Crick proposed that 
genetic information flows from DNA to RNA which in turn serves as a template for protein synthesis1. This was 
later called the central dogma of molecular biology. Five years later, in 1961, Jacob & Monod showed that 
protein synthesis from DNA indeed required an intermediate RNA molecule which they termed as messenger 
RNA or simply mRNA. Although central to the dogma, RNA was proposed to be merely a messenger for 
transferring the genetic information stored in the DNA to proteins – which were thought to be the major 
drivers of all the cellular functions.  
At this point, it was also becoming clear that not all RNA molecules code for proteins. Early work done in 
Zamecnik lab indicated that an RNA molecule was involved in protein synthesis as an intermediate carrier of 
amino acids. Soon after this discovery, several other such molecules were discovered and it became apparent 
that these molecules constitute an entire class of RNAs and were named as transfer RNAs (tRNAs)2. These 
were the RNAs with non-protein-coding function. Around the same time, a link between rRNAs and ribosomes 
had been established3. Following the discovery of these structural RNAs, several other small RNAs were 
discovered. Small nuclear RNAs (snRNAs) were found to be involved in RNA splicing4, 5. Small nucleolar RNAs 
(snoRNAs) were found to be involved in rRNA processing6. With the discovery of ribozymes, it became 
apparent that RNA had additional roles outside protein synthesis7, 8. Thereafter, advancements in sequencing 
methods revealed several small (e.g. microRNAs) as well as long regulatory RNAs (e.g. XIST) with no protein-
coding potential. miRNAs were found to be 20-22 nucleotide (nt) long RNA molecules which could bind their 
complementary mRNAs and negatively regulate their expression. XIST was identified to be a 15 kilobase (kb) 
long RNA arising from the X chromosome inactivation center and to coordinate X chromosome inactivation9. 
Next-generation sequencing (NGS) technology revealed that the majority of the genome gave rise to non-
protein-coding or simply non-coding RNAs (ncRNAs)10. These were arbitrarily divided into two groups based on 
their lengths: small ncRNAs (less than 200 nt) and the rest were called long ncRNAs (lncRNAs). 
1.1.2. Classification 
LncRNAs can be classified on the basis of several attributes, for example, their length, their genomic location, 
and context, their association with genomic elements of known functions, their mechanism of function and so 
forth11, 12. The most common method of lncRNA classification is based on their genomic location in context to 
previously annotated protein-coding genes. lncRNA loci are widely distributed throughout the mammalian 
genome and they can be transcribed either from intergenic regions (such transcripts are called long intergenic 
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RNAs or lincRNAs) or from intragenic regions overlapping with other protein-coding genes (Figure 1). Nearly 
60% of all lncRNAs fall into the category of long Intergenic RNAs13. lincRNAs can arise from independent 
promoters as well as divergently from bidirectional promoters which they share with other protein-coding 
genes (Figure 1A). Intragenic lncRNAs can be further classified as sense or antisense, depending on the 
orientation of the lncRNA with respect to its neighboring gene with which they overlap. They can arise either 
from external promoters that lie outside the gene that they overlap or from internal promoters that lie inside 
the gene that they overlap (Figure 1B). Antisense lncRNAs represent the second largest class and account for 
30% of the total annotated lncRNAs13. 
 
Figure 1: lncRNA classification based on genomic location 
Schematic representation of lncRNA loci (in gray) distribution across the human genome and their classification based 
on their location in context to previously annotated protein-coding genes (in black). (A) Intergenic lncRNAs do not 
overlap with any protein-coding gene and can be transcribed from either independent promoters or bidirectional 
promoters. (B) Intragenic lncRNAs can be further divided into Antisense or Sense lncRNAs depending on their 
orientation with respect to their overlapping protein-coding genes and can be transcribed from either an external or 
an internal promoter. 
 
 
1.1.3. Function and mechanism of action 
LncRNAs are a functionally diverse group of molecules and play important roles in several cellular processes 
such as cell cycle regulation, cell migration, differentiation etc. and thus contribute to normal development 
and diseases, such as cancer14-17. Through their ability to interact with DNA, RNA, and protein, they can 
regulate gene expression at transcriptional as well as post-transcriptional levels. 
Intergenic lncRNA Intragenic lncRNA
Independent promoter
Bidirectional promoter
Antisense Sense
External promoter
Internal promoter
Antisense Sense
A B
lncRNA Protein coding gene
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LncRNAs can regulate the transcription of their target genes either by binding and recruiting chromatin 
modifying complexes or by the simple act of their transcription alone18-20. Moreover, transcriptional regulation 
by lncRNAs can be either in cis or in trans. A cis-acting lncRNA regulates the transcription of a gene residing on 
the same chromosome from which they are transcribed. On the other hand, a trans-acting lncRNA regulates 
the transcription of the gene(s) located on another chromosome(s)20. An example of a cis-acting lncRNA is 
ANRIL (also known as p15AS or CDKN2B-AS), which is overexpressed in cancer. ANRIL is transcribed antisense 
to the tumor suppressor locus of INK4a/ARF/INK4b (p16/p14/p15) where it binds and recruits the PRC2 
complex to induce histone H3 lysine 27 (H3K27) methylation, thereby repressing transcription from this 
locus21-23(Figure 2A). Another example of in cis-transcriptional regulation by a lncRNA is that of the hemoglobin 
α1 gene (HBA1) repression by LUC7L. In a class of α-thalassemia patients, an aberrant read-through 
transcription of LUC7L across its antisense protein-coding gene HBA1 results in methylation of its promoter 
CpG island, thereby silencing HBA1 expression and causing the disease24 (Figure 2B). The metastasis-associated 
lung adenocarcinoma transcript 1 (MALAT1) is a marker for lung cancer metastasis and a regulator cell 
migration and cell cycle25-27. It is localized in the nuclear speckles where it binds the unmethylated Polycomb 2 
(Pc2), a component of the PRC1 complex and regulates the transcription of Pc2-bound genes following serum 
restimulation. Apart from recruiting histone modifying complexes or inducing DNA methylation, the act of 
lncRNA transcription can also regulate the expression of their overlapping gene. Such an effect is called 
transcriptional interference and is mediated by direct collision of RNA polymerases (Figure 2C). An example of 
transcriptional interference is the regulation of the IME4 gene by its antisense transcript RME2 (Regulator of 
Meiosis). The expression of RME2 in haploid Saccharomyces cerevisiae cells prevents IME4 expression28, 29. In 
diploid cells, however, the transcription of RME2 is repressed, thereby allowing IME4 to be induced during 
meiosis. HOTAIR (HOX transcript antisense RNA) is an example of a trans-acting lncRNA, which is an antisense 
transcript to the HOXC locus. HOTAIR silences the HOXD locus in trans through its interaction with the PRC2 
complex30 (Figure 2D). 
Post-transcriptionally, lncRNAs can regulate gene expression in several ways31. LncRNA BACE1-AS plays an 
important role in Alzheimer’s disease where it base pairs with its antisense mRNA of the β-secretase-1 
(BACE1), masking a microRNA (miRNA) binding site, thereby preventing it from degradation32, 33 (Figure 2E). 
The increased β-secretase-1 levels contribute to the pathophysiology of Alzheimer’s disease. The mouse 
Uchl1AS lncRNA base pairs with the 5’ end of its antisense Uchl1 mRNA and upregulates its translation through 
an embedded SINEB2 repeat element34. LncRNAs can also regulate gene expression by acting as miRNA 
sponges35. Such lncRNAs are called competing endogenous RNAs (ceRNAs). Linc-MD1 regulates the muscle 
differentiation by sponging miR-133 and miR-135 to regulate the expression of MAML1 and MEF2C36.LncRNAs 
can also bind proteins to regulate their stability. 
LncRNAs can also play a role outside gene expression regulation. An example is the lncRNA Telomerase RNA 
component (TERC) which is involved in the maintenance of the telomere by serving as a scaffold for 
telomerase components and template for repeat addition37. 
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Figure 2: lncRNA mechanisms of action 
A-C: Examples of LncRNAs regulating transcription in cis (A) ANRIL nascent transcript binds and recruits PRC2 to the 
INK4 locus to induce H3K27 trimethylation, thereby silencing this locus. (B) Aberrant transcription of the LUC7L 
lncRNA over the HBA1 promoter results in promoter DNA methylation, thereby silencing HBA1 expression. (C) 
LncRNAs can regulate the expression of their overlapping genes by transcriptional interference mediated by a direct 
collision between the RNA polymerases of the two genes. 
D: HOTAIR binds and recruits PRC2 to the HOXD locus to regulate its transcription in trans. 
E: BACE1-AS lncRNA base pairs with its sense mRNA BACE1 to mask the miR-485-5p binding site, thereby preventing 
miRNA-mediated degradation. 
Figure adapted from Pelechano et al., Nature Reviews Genetics 201319 
 
1.1.4. LncRNAs in DNA Damage Response Pathway 
The DNA damage response (DDR) pathway is a coordinated cellular response to genotoxic stress that could 
potentially lead to genomic instability, altered protein production or loss of genetic material. Mutations and 
strand breaks can activate DNA damage checkpoints to arrest the cell cycle to allow for the repair of DNA 
lesions. If the DNA repair fails or the DNA damage is too massive, apoptosis is triggered to ensure the removal 
of cells carrying damage and prevention of mutation accumulation38.  
In the past few years, several lncRNAs have emerged as major regulators of the DDR pathway16, 39. The first 
example of a lncRNA involved in the DDR pathway was that of the ncRNA-CCND140. ncRNA-CCND1 is induced 
from the promoter upstream region of CCND1 upon DNA damage caused by ionizing radiation. It recruits the 
RNA binding protein TLS to the CCND1 promoter, which in turn, inhibits the CREB-binding protein (CBP) and 
p300 histone acetyltransferase activities, thereby preventing CCND1 expression40, 41. ANRIL is induced upon 
DNA damage via the ATM-E2F pathway and suppresses the expression of its overlapping protein-coding gene 
INK4b (p15) to regulate the cell cycle42. A non-coding isoform of WRAP53 is transcribed from the first exon of 
TP53 in antisense manner and regulates p53 mRNA stability as well as induction upon DNA damage by binding 
to the 5’ untranslated region of the p53 mRNA43. PARTICLE (promoter of MAT2A-antisense radiation-induced 
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circulating lncRNA) is induced from the MAT2A promoter upon DNA damage. It forms a DNA-lncRNA triplex 
with the MAT2A promoter and recruits G9a and PRC2 to silence MAT2A transcription44.  
Not all lncRNAs involved in DNA damage are cis-acting. Many lncRNAs act in trans to modulate the DDR 
pathway. DDSR1 is induced in an ATM-NF-κB pathway-dependent manner and interacts with BRCA1 to 
enhance DNA repair via homologous recombination45. LINP1 serves as a scaffold for Ku80 and DNA-PKc to 
increase NHEJ-mediated repair efficiency46. NORAD serves as a molecular decoy for PUMILIO to regulate 
genome stability47. ERIC is an E2F-regulated lncRNA which controls DNA damage-induced apoptosis48. 
TP53 (p53) is a major transcription factor involved in the DDR. DNA damage stabilizes p53 which then activates 
the transcription of several protein-coding genes to coordinate the cellular response to DNA damage49, 50. A 
growing body of literature indicates that p53 also regulates expression of numerous lncRNAs and they can, in 
turn, regulate the p53 signaling51-54. LincRNA-p21, PANDAR (p21 associated ncRNA DNA damage activated RNA, 
also known as PANDA) and DINO (damage induced noncoding) are induced from promoter upstream regions 
of the CDKN1A (p21) gene upon DNA damage in a p53-dependent manner. While lincRNA-p21 and PANDAR 
modulate apoptosis by regulating the expression of several p53 target genes55, 56, DINO interacts with p53 
through a stem loop motif and stabilizes it, thereby activating p53 target genes54, 57. LincRNA-RoR is induced 
upon DNA damage in a p53-dependent manner and binds hnRNP I to repress p53 mRNA translation, thereby 
constituting a negative feedback loop58. PINT is induced in a p53-dependent manner upon DNA damage and 
coordinates PRC2-mediated gene silencing of several p53 target genes59 (Figure 3).  
 
Figure 3: LncRNAs in the p53 regulatory network 
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p53 is stabilized upon DNA damage and activates transcription of numerous lncRNAs. LncRNA-21, PANDAR, and DINO 
are all transcribed from the promoter upstream region of the p53 target gene CDKN1A. LincRNA-p21 binds to hnRNP-
K and this complex represses the transcription of several p53 target genes. PANDAR binds to and sequesters the pro-
apoptotic transcription factor NF-YA thereby resulting in reduced apoptosis. DINO binds and stabilizes p53, thereby 
leading to activation of the p53 target gene. LncRNA-RoR binds and sequesters hnRNP-I which otherwise binds to the 
p53 mRNA and enhances its translation, thereby leading to decreased p53 mRNA translation and mitigation of p53 
response. PINT binds to PRC2 complex to silence the expression of several pro-apoptotic and anti-proliferative p53 
target genes. 
 
In summary, these and several other examples prove the importance of lncRNAs in the DDR pathway44, 60-67. 
1.2. CRISPRs 
1.2.1. Introduction 
CRISPRs (Clustered regularly interspaced palindromic repeats) were first discovered in archael68 and later in 
bacterial69, 70 genomes as arrays of near perfect palindromic repeats separated by spacer regions derived from 
invading phages and plasmids. These serve as a memory of previous infections and together with CRISPR-
associated (Cas) proteins constitute a prokaryotic adaptive immune system70-73. The CRISPR/Cas system 
incorporates DNA fragments from invading plasmids or phages into the host CRISPR locus, which is then 
transcribed and processed into crRNAs, which in turn guide the Cas proteins to recognize and cleave the 
invading genome73. CRISPR systems can be classified into several types depending on their components and 
mechanisms of action74.  
The type II CRISPR system from S. pyogenes is the most widely studied and was the first system to be adapted 
for mammalian genome editing75, 76. In its simplest form, this system consists of two components: the Cas9 
nuclease enzyme and a single guide RNA (sgRNA)76, 77. The first 20 nucleotides (nt) on the 5’ end of the sgRNA 
can hybridize with complementary DNA sequence and thus determine targeting specificity of this system. The 
rest of the sgRNA sequence binds the Cas9 nuclease and thus help to recruit the Cas9-sgRNA complex to its 
target, where Cas9, using its two nuclease domains (HNH and RuVc), generates a double-stranded break (DSB) 
within the base paired region. Since the target specificity is determined by only a 20 nt RNA sequence, and the 
nuclease remains the same, this system can be readily programmed to target any sequence of choice provided 
it is followed by a 3 bp PAM sequence (NGG, where N is any of the four bases and G is Guanine)(Figure 4A). 
Cas9-induced DSB can be repaired by one of the two intrinsic cellular repair mechanisms, namely, non-
homologous end joining repair (NHEJ)78 or homology-directed repair (HDR)79. NHEJ is an error-prone 
mechanism and causes random insertions or deletions (indels) of base pairs around the cut site in the process 
of joining the break (Figure 4B). HDR, on the other hand, utilizes the homologous chromosome as a template 
for error-free repair of the break via homologous recombination (Figure 4C). This ability of Cas9 to bind and 
cleave double-stranded DNA (dsDNA) in an easily programmable and a sequence-specific manner makes it a 
very powerful tool for genome engineering. 
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Figure 4: Cas9-mediated genome editing 
(A) The Cas9-sgRNA complex recognizes target DNA sequences through a 20 nt region on the 5’ end of the sgRNA, 
which base pairs with its complementary sequence in the target genome. If the PAM sequence (NGG) is present 
adjacent to the target sequence, Cas9 generates a DSB using its two nuclease domains (HNH and RuvC). Such a DSB 
can be repaired using either (B) the NHEJ pathway, which results in random insertions or deletions around the cut site 
or (C) the HDR pathway, which uses the homologous DNA as a template to carry out the precise repair. 
 
1.2.2. Applications for lncRNA research 
Cas9 is widely used to generate DSBs in the open reading frame (ORF) of a protein-coding gene, resulting in 
indel formation via the NHEJ repair pathway. This, in turn, induces frameshift mutations resulting in an 
effective knockout of the targeted protein-coding gene76 (Figure 5A). This method is in general not applicable 
for knocking out lncRNAs as unlike their protein-coding counterparts, they lack an ORF, and a small indel 
mutation is unlikely to change its structure or expression (Figure 5B). It can be used to generate functional 
knockouts in the special case when the sequences of the lncRNA transcript responsible for carrying out 
transcript-dependent molecular functions are already known or well characterized. However, that is not the 
case for most of the lncRNAs as a vast majority of lncRNAs still remain uncharacterized. Moreover, predicting 
the active parts of a lncRNA is currently not possible as they can exert their molecular functions through 
diverse mechanisms. Also, for lncRNAs which exert their phenotype by the act of their transcription, a Cas9-
induced indel mutation is highly unlikely to affect its transcription and thus its function, unless Cas9 is targeted 
to a genomic element controlling the lncRNA transcription. Given that lncRNAs often arise from regulatory 
elements which they share with other genes (e.g. lncRNAs arising from enhancer regions), this approach can 
potentially lead to the detection of false phenotypes. 
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Cas9 can also be used to induce small or large genomic deletions by simultaneously generating multiple DSBs80, 
81. This approach can be used to generate lncRNA knockouts by either deleting their promoters82-87 or the 
entire lncRNA genes84, 88 (Figure 5C). In any case, genomic excisions, howsoever small, can lead to the deletion 
of regulatory DNA elements, which might affect transcription of other genes and give rise to phenotypes which 
are originally not attributable to the lncRNA84, 89-91. Since it is impossible to consider the position of all potential 
genomic regulatory elements, as they remain largely uncharacterized, any deletions should be preceded by a 
detailed examination of the genomic region of interest. 
Alternatively, the HDR mechanism can be exploited to engineer precise changes in the genome by supplying a 
donor DNA template which harbors the desired mutation(s) and has homology to the region around the cut 
site of the target DNA. In this manner, the Cas9-induced DSBs can be used for gene corrections or to knockin 
DNA elements for gene overexpression, knockout as well as tagging92, 93. This approach can be used to 
knockdown lncRNA expression using Cas9 by homology-directed knockin of a transcriptional termination signal 
or RNA destabilizing elements immediately downstream of the TSS of the lncRNA gene84, 90 (Figure 5D). This 
method was initially proposed and utilized by the Diederichs lab to knockdown MALAT1, using zinc finger 
nucleases (ZFNs) instead of Cas994. Although superior to the Cas9 mediated deletion approach, homology-
directed knockin can also potentially lead to disruption of any underlying regulatory elements controlling 
transcription of other genes (e.g. a transcription factor binding site). Moreover, HDR being a less efficient 
process as compared to NHEJ, this approach can be extremely labor intensive as it involves clonal expansion 
and screening for positive clones. 
Mutation of both the nuclease domains of Cas9 results in a catalytically dead Cas9 (dCas9), which lacks the 
endonuclease activity but still possesses its sgRNA-dependent DNA-binding activity. dCas9 can be fused to 
effector domains and co-expressed with sgRNAs to generate custom transcription factors. dCas9, when 
recruited to the vicinity of the promoter of a gene, can interfere with either transcription initiation or 
elongation, thereby resulting in reduced transcription95, 96. dCas9 fused to the transcriptional repressor 
domains like KRAB (Krüppel-associated box domain of ZNF10)97 or SID (mSin interacting domain of Mad1)98, 99 
results in an even more potent inhibitor of transcription (CRISPR interference or CRISPRi)96, 100 (Figure 5E). On 
the other hand, dCas9, when fused to transcriptional activator domains like VP160, p65, or Rta, can induce 
target gene expression from the endogenous promoter of their target genes (CRISPR activation or CRISPRa)101-
103 (Figure 5F). CRISPRi/CRISPRa with dCas9-based transcription factors have been used to perform genome-
wide loss-of-function as well as gain-of-function screens for protein-coding or lncRNA genes104-108. 
CRISPRi/CRISPRa systems have several advantages for lncRNA research: (1) Modulation of transcription from 
the endogenous promoter ensures that the in cis functions of the lncRNA can also be observed, which would 
otherwise be undetectable by RNA interference (RNAi)-mediated knockdown or plasmid-based 
overexpression. (2) lncRNA genes often give rise to several splice isoforms, and modulation of transcription 
from the endogenous promoter would lead to modulation of all splice variants in their natural ratios. (3) Unlike 
the Cas9-mediated deletion or insertion approaches, these systems do not perturb any underlying genomic 
regulatory elements. (4) Since no clonal selection is involved, a CRISPRi/CRISPRa mediated loss-of-function or 
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gain-of-function model can be generated in a much shorter time span as compared to Cas9-mediated deletion 
or insertion approaches. 
 
Figure 5: CRISPR/Cas9 applications for lncRNA research 
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A,B: A Cas9-induced DSB, when repaired using NHEJ, can lead to insertion or deletion of a few base pairs (indel 
mutations). Such mutations in the ORF of a (A) protein-coding gene often lead to a frameshift and premature 
translational termination, thereby leading to knockout of the full-length protein. However, for (B) lncRNAs, they do 
not affect their function or expression. 
C,D: Simultaneous induction of two DSBs using Cas9 can lead to excision of the DNA fragment between them. This can 
be used to delete the (C) promoter or (D) the entire gene body of a lncRNA leading to its knockout. 
E,F: dCas9 can be used to modulate transcription of a lncRNA from its endogenous promoter. dCas9 can be fused to 
either (E) a KRAB domain which leads to promoter methylation thereby inhibiting the transcription of the lncRNA, or 
(F) to a VP16 domain or a derivative, which interacts with multiple components of the transcription machinery and 
enhances RNA Pol-II recruitment, thereby activating transcription. 
 
Overall, CRISPR/Cas9 systems offer a very powerful and easy to use lncRNA manipulation toolbox.  
1.3. Previous results and basis of the dissertation 
To identify novel lncRNAs involved in the DDR, Evgenij Fiškin treated A549 and HepG2 cells with the DNA-
damaging agents Etoposide, Cisplatin, and Bleomycin or vehicle control DMSO and performed a microarray 
expression analysis together with Dr. Maria Polycarpou-Schwarz to identify differentially expressed lncRNAs. 
LncRNA NOP14-AS1 was identified as the most promising candidate as it was induced in both cell lines upon 
treatment with all the three DNA-damaging drugs (Figure 6A). Julia Neugebauer found that inversely to 
NOP14-AS1, the expression of its neighboring antisense gene NOP14 was downregulated upon DNA damage 
(Figure 6B). 
The preliminary data on regulation of NOP14-AS1 upon DNA damage and its negative correlation with NOP14 
indicated that NOP14-AS1 lncRNA or its transcription could be functionally linked to NOP14 mRNA expression 
or vice versa as it had been proposed for several other sense-antisense pairs of lncRNA and mRNA genes19, 20, 
109. 
 
Figure 6: Identification of NOP14-AS1 as a DNA damage-inducible lncRNA 
A: Microarray analysis heat map of lncRNAs and mRNAs differentially expressed in A549 (left panel) and HepG2 (right 
panel) cells treated with 50 μM Etoposide (ETO) / 50 μM Cisplatin (CIS) / 20 μM Bleomycin (BLEO) or vehicle control 
DMSO for 8 hours.  
Treatments performed by Evgenij Fiškin, microarray hybridization performed by Dr. Maria Polycarpou-Schwarz, 
microarray analysis performed by Prof. Dr. Sven Diederichs. Data also used for a manuscript under review for 
publication: Goyal et al. 
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B: HepG2 cells were treated with 50 μM Etoposide (ETO) or vehicle control DMSO for 8 hours. RT-qPCR results for 
NOP14-AS1 and NOP14 normalized to Cyclophilin A and DMSO controls. Error bars represent SD (n=2).  
Experiment performed by Julia Neugebauer. 
 
1.4. Aim of this study 
In this study, the regulation of NOP14-AS1, as well as its neighboring genes NOP14 and MFSD10 in DNA 
damage should be further characterized. Particular aims included  
1) the reproduction of the preliminary observation of an inverse co-regulation between NOP14-AS1 and 
NOP14.  
2) the analysis of the regulatory mechanism with a focus on TP53 (p53) since several DNA damage induced 
lncRNAs are p53-dependent. 
3) establishing and testing loss-of-function and gain-of-function-models for NOP14-AS1 and NOP14. Since 
antisense lncRNAs often regulate the expression of their neighboring gene in cis, these models should be 
capable of mimicking such a regulatory mechanism. These models serve to study the impact and mechanism of 
NOP14-AS1 on the NOP14 expression or vice versa. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals and enzymes 
Table 1: List of chemicals and enzymes used in this study 
Name Sequence 
30% Acrylamide/Bis Solution, 37.5:1  Carl Roth 
Acetic Acid  Merck Biosciences 
Acetone Sigma-Aldrich 
Agarose, LE  Biozym 
Ammonium Persulfate Electrophoresis Reagent Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Beta-Mercaptoethanol  Sigma-Aldrich 
Bicinchoninic Acid (BCA)  Sigma-Aldrich 
Blasticidin Invivogen 
Bleomycin Merck Millipore 
BSA Roche 
Calcium Chloride  Carl Roth 
Chloroform  Carl Roth 
Cisplatin Merck Millipore 
Copper(II) sulfate solutions  Sigma-Aldrich 
Dharmafect GE Dharmacon 
Dithiothreitol (DTT)  Roche 
DMEM  Sigma-Aldrich 
DMSO  AppliChem 
DNase I  Roche 
dNTP mix  Thermo Fisher Scientific 
Doxorubicin Merck Millipore 
Dream Taq DNA-Polymerase Thermo Fisher Scientific 
EDTA  Gerbu 
EDTA-free protease inhibitor mixture tablets  Roche 
Ethanol, absolute Sigma-Aldrich 
Ethidium Bromide  Carl Roth 
Etoposide Cayman Chemical 
Fast Digest AgeI Thermo Fisher Scientific 
Fast Digest BamHI Thermo Fisher Scientific 
Fast Digest BsmBI Thermo Fisher Scientific 
Fast Digest BsrGI Thermo Fisher Scientific 
Fast Digest KpnI Thermo Fisher Scientific 
Fast Digest NheI Thermo Fisher Scientific 
Fast Digest XbaI Thermo Fisher Scientific 
FastDigest enzymes  Thermo Fisher Scientific 
FBS Thermo Fisher Scientific 
Formaldehyde  Thermo Fisher Scientific 
GeneRuler 100bp Plus DNA Ladder  Thermo Fisher Scientific 
GeneRuler 1kb DNA Ladder Thermo Fisher Scientific 
Isopropanol  Sigma-Aldrich 
L-glutamine Sigma-Aldrich 
Lipofectamine 2000 Thermo Fisher Scientific 
Lipofectamine RNAiMAX Thermo Fisher Scientific 
Methanol Sigma-Aldrich 
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Table 1: List of chemicals and enzymes used in this study 
Name Sequence 
NP-40 Sigma-Aldrich 
Nutlin-3 Sigma-Aldrich 
Opti-MEM Thermo Fisher Scientific 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific 
Polybrene Sigma-Aldrich 
Powdered LB Thermo Fisher Scientific 
Powdered Skimmed milk Fluka 
Power SybrGreen Master Mix 2X Thermo Fisher Scientific 
Proteinase K Sigma-Aldrich 
Puromycin Thermo Fisher Scientific 
Q5 High-Fidelity DNA Polymerase New England Biolabs 
Random Hexamer Primers Thermo Fisher Scientific 
RevertAid Reverse Transcriptase Thermo Fisher Scientific 
RiboLock RNase Inhibitor Thermo Fisher Scientific 
Roti-Aqua-P/C/I for RNA extraction Carl Roth 
RPMI 1640 Sigma-Aldrich 
SDS Carl Roth 
Sodium Acetate Carl Roth 
Sodium Chloride Sigma-Aldrich 
Sodium Deoxycholate AppliChem 
Super Signal West Femto Chemiluminescent Substrate Thermo Fisher Scientific 
Super Signal West Pico Chemiluminescent Substrate Thermo Fisher Scientific 
T4 DNA ligase Thermo Scientific 
TEMED Carl Roth 
TRI Reagent Sigma-Aldrich 
TritonX-100 Gerbu 
Trizma base Sigma-Aldrich 
Trypsin-EDTA (0.05%, 0.25%)  Thermo Fisher Scientific 
Tween-20  MP Biomedicals 
UltraPure DNase/RNase-Free Distilled Water Thermo Fisher Scientific 
 
2.1.2. Kits and disposables 
Table 2: List of kits and disposables used in this study 
Name Company 
1.5 ml Reaction Tubes Eppendorf 
10 cm dishes, 96 x 20mm TPP 
12-well plates TPP 
15 cm dishes, 146x21 mm TPP 
15 ml Falcon Tubes TPP 
2 ml Cryotubes Greiner Bio-One 
2 ml Reaction Tubes Eppendorf 
24-well plates TPP 
50 ml Falcon Tubes TPP 
6-well plates TPP 
Amersham Hybond N+ nylon membrane GE Healthcare 
Axyprep Plasmid MiniPrep Kit Axygen 
Combitips advanced, 0.2, 0.5, 2.5, 5, 10, and 25 ml Eppendorf 
Filter paper Whatman 3MM Whatman 
Filter Tips 1000 µl Nerbe Plus 
Filter Tips 2, 20 and 200 µl Neptune 
GeneJET Gel Extraction Kit Thermo Fisher Scientific 
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Table 2: List of kits and disposables used in this study 
Name Company 
Millex-HV 0.45 µm Merck Millipore 
Multichannel pipette tips LiteTouch System LTS 20µl Rainin 
PCR SingleCap 8er-SoftStrips 0.2 ml Biozym 
Poly-L-Lysine coated 6-well plates Greiner Bio-One 
PureLink HiPure Plasmid Maxiprep Kit Thermo Fisher Scientific 
PureLink HiPure Plasmid Midiprep Kit Thermo Fisher Scientific 
QuikChange II Site-Directed Mutagenesis Kit Agilent Genomics 
Serological pipette PS 10 ml Nerbe Plus 
Serological pipette PS 25 ml Nerbe Plus 
Serological pipette PS 5 ml Nerbe Plus 
TOPO TA cloning kit Thermo Fisher Scientific 
 
2.1.3. Technical equipment 
Table 3: Technical equipment used in this study 
Name Company 
Applied Biosystems StepOnePlus cycler  Thermo Fisher Scientific 
BioPhotometer Plus  Eppendorf 
Cell incubator Labotect C200  Labotect  
ChemoCam ECL Imager 3.2 Intas 
Gilson Pipetman Pipette Set  Gilson  
INFORS HT - Ecotron (Bacterial Shaker)  INFORS HAT  
INTAS UV gel-imager  INTAS 
Isotemp 202 (Waterbath)  Thermo Fisher Scientific 
Leica DM IRB microscope  Leica 
Metal-Block-Thermostat MBT-250  Kleinfeld 
Mini Trans-Blot Electrophoretic Transfer Cell  Bio-Rad 
Mini Protean Minigel System  Bio-Rad 
Multistep pipette (Multipette stream)  Eppendorf 
Multiwell pipette (pipet lite) Rainin 
NanoDrop 1000 Spectrophotometer  Thermo Fisher Scientific 
Orbital Shaker DOS-10L  NeoLab 
PCR thermal cycler PTC-200  Bio-Rad 
PowerPac Basic, Power Supply  Bio-Rad  
Sartorius pH Meter PB-11  Sartorius 
SterilGARD III Advance cell culture hood  The Baker Company  
Trans-Blot SD Semi-Dry Transfer Cell  Bio-Rad 
Vortex Mixer  NeoLab  
 
2.2. Methods 
2.2.1. Molecular cloning 
lentidCas9-Blast: The Cas9 coding sequence in the lentiCas9-Blast plasmid110 (a gift from Prof. Feng Zhang, 
obtained through addgene, plasmid #52962) was mutated to generate the nuclease-deficient dCas9 (D10A and 
H841A)95, using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) according to 
manufacturers recommendation. In the first step the Aspartic acid at the 10th position of the Cas9 coding 
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sequence was mutated to Alanine (D10A), and in the second step, the Histidine at the 841st position of the 
Cas9 coding sequence was mutated to Alanine (D10A). For each step, a final reaction of 50 μl with 1x PfuUltra 
HF DNA polymerase buffer, 1 μl dNTPs, 125 ng forward and reverse primer each (Table 4), 10 ng parental 
plasmid and 1 μl (2.5 Units) of the PfuUltra HF DNA polymerase was prepared. The site-directed mutagenesis 
PCR was performed as follows: 
 Initial denaturation at 95°C for 2 min   
 95°C for 30 sec 
x 18 cycles  60°C for 30 sec 
 72°C for 15 min 
 
The parental plasmid was subsequently digested by adding 1 μl of Dpn I to the reaction mix followed by 
incubation for 1 h at 37°C. 1 μl of this reaction was transformed into 50 μl chemically competent MachI cells. 
Following transformation, plasmid DNA was isolated using the Axyprep Plasmid MiniPrep Kit according to the 
manufacturer’s recommendations. Plasmids thus obtained were screened for intended mutation using sanger 
sequencing of the region of interest. The final plasmid with D10A and H841A mutations was named lentidCas9-
Blast. 
 
 
 
lentidCas9-KRAB-Blast: The cDNA for the repression domain of KRAB (amino acids 11-75)99 fused with an 
XTEN-based linker111 on its N-terminal end was synthesized (GeneArt/ThermoFisher Scientific). This was cloned 
in frame downstream of dCas9 in the BsrGI and BamHI restriction sites. The resulting plasmid was named 
lentidCas9-KRAB-Blast. 
 
 
 
lentidCas9-KRAB-PURO iv sgRNA: The dCas9-KRAB coding sequence was cut out from the lentidCas9-KRAB-
Blast vector using FastDigest AgeI and BamHI (ThermoFisher Scientific), cloned into the same sites in 
lentiCRISPR v2110 (a gift from Prof. Feng Zhang, obtained through addgene, plasmid #52961) replacing Cas9. An 
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improved sgRNA scaffold112 was synthesized (GeneArt) and cloned into the KpnI-NheI sites replacing the 
existing sgRNA. The resulting plasmid was named lentidCas9-KRAB-PURO iv sgRNA (iv = improved version).  
 
 
 
lentidCas9-VP160-PURO iv sgRNA: The activation domain VP160 (10 tandem repeats of VP16) was PCR 
amplified from pAC154-dual-dCas9VP160-sgExpression vector113 (a gift from Prof. Rudolf Jaenisch, obtained 
through addgene, plasmid # 48240) using XbaI VP160 F and BamHI VP160 R primers (Table 4). This was cloned 
into XbaI-BamHI restriction sites of the lentidCas9-KRAB-PURO iv sgRNA to replace the KRAB domain in frame 
with dCas9. The resulting plasmid was named lentidCas9-VP160-PURO iv sgRNA.  
 
 
 
PX458-2X-sgRNA: This plasmid was generated by Berta Duran Arqué under the supervision of Ashish Goyal. 
Briefly, individual sgRNAs (NOP14-AS1 US sgRNA and NOP14-AS1 DS sgRNA) for NOP14-AS1 deletion were 
cloned individually into PX45892 (a gift from Prof. Feng Zhang, obtained through addgene, plasmid #48138). 
The U6 – NOP14-AS1 DS sgRNA expression cassette from the PX458 – NOP14-AS1 DS sgRNA plasmid was PCR 
amplified and cloned into XbaI – KpnI restriction sites of the PX458 – NOP14-AS1 US sgRNA plasmid. The 
resulting plasmid was named PX458-2X-sgRNA. 
 
lenti EGFP-Blast: The EGFP open reading frame (ORF) was PCR amplified from PX458  using AgeI EGFP F and 
BamHI EGFP R primers (Table 4). This was cloned into AgeI-BamHI restriction sites of the lentiCas9-Blast 110 to 
replace the Cas9 ORF in frame with the downstream Blasticidin ORF. The resulting plasmid was named lenti 
EGFP-Blast. 
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lenti NOP14-Blast: The NOP14 ORF was PCR amplified from cDNA generated from NCI-H460 cells first using 
NOP14 cDNA F and NOP14 cDNA R primers and then using AgeI NOP14 F and BamHI NOP14 R primers (Table 
4). This was cloned into AgeI-BamHI restriction sites of the lentiCas9-Blast to replace the Cas9 ORF in frame 
with the downstream Blasticidin ORF. The resulting plasmid was named lenti NOP14-Blast. 
 
Table 4: List of primers used for molecular cloning 
Name Target Sequence 
Cas9D10A F Cas9D10 5’-GAAGTACAGCATCGGCCTGGCCATCGGCACCAACTCTGTGG-3’ 
Cas9D10A R Cas9D10 5’-CCACAGAGTTGGTGCCGATGGCCAGGCCGATGCTGTACTTC-3’ 
Cas9H481A F Cas9H481 5‘-GTCCGACTACGATGTGGACGCCATCGTGCCTCAGAGCTTTC-3‘ 
Cas9H481A R Cas9H481 5‘-GAAAGCTCTGAGGCACGATGGCGTCCACATCGTAGTCGGAC-3‘ 
XbaI-sgRNA-F sgRNA scaffold 5’-AAGTTCTAGAGGGCCTATTTCCCATGA-3’ 
KpnI-sgRNA-R sgRNA scaffold 5’-ATATGGTACCTTGTCTGCAGAATTGGC-3’ 
XbaI VP160 F VP160 5’-ATGCTCTAGAGACGCGCTGGACGATTTCG-3’ 
BamHI VP160 R VP160 5’-ATATGGATCCCAACATATCCAAATCGAAGTCATCGAGC-3’ 
AgeI EGFP EGFP 5’-ATACCGGTCCACCATGGTGAGCAAGGGCGAGGAGC-3’ 
BamHI EGFP EGFP 5’-ATAGGATCCCTTGTACAGCTCGTCCATG-3’ 
NOP14 cDNA F NOP14 5’-CCATGGCGAAGGCGAAGAAGGTCGGGG-3’ 
NOP14 cDNA R NOP14 5’-TTATTTTTTGAACTTTTTCCTCTTCAGAGCCTTCC-3’ 
AgeI NOP14 F NOP14 5’-CAGGACCGGTCCACCATGGCGAAGGCGAAGAAG-3’ 
BamHI NOP14 R NOP14 5’-GCCGGATCCTTTTTTGAACTTTTTCCTCTTCAGAG-3’ 
5’-RACE GSP NOP14-AS1 5’-GGGTGCTGGGGTTCTCCATTCAGGACA-3’ 
3’-RACE GSP NOP14-AS1 5’-GTCTCCTCCCACCTCCGAGAGTGCAGTG-3’ 
 
2.2.2. Bacterial transformation 
50 μl chemically competent Mach I cells were incubated with the indicated amount of plasmid/reaction mix to 
be transformed. Following 30 min incubation on ice, the transformation reaction was transferred to 42°C for 
40 sec and then back on the ice for 2 mins. 150 μl sterile LB medium (without any antibiotics) was added to the 
transformation reaction and it was incubated for 1 h at 37°C under constant shaking. 100 μl of the 
transformation reaction was spread plated on LB Agar plates containing 100 µg/mL Ampicillin and incubated at 
37°C overnight. Single colonies were picked and inoculated in 2 ml liquid LB medium containing 100 µg/mL 
Ampicillin.  
2.2.3. Polymerase chain reaction (PCR) 
All PCR reactions were performed using Q5® High-Fidelity DNA Polymerase (unless specified otherwise) 
according to manufacturer’s recommendations. Briefly, a final reaction of 50 μl with 1x Q5® Reaction Buffer, 
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200 μM dNTP mix, 0.5 μM forward and reverse primer each, 10-500 ng template DNA and 1 μl of the Q5® 
High-Fidelity DNA Polymerase was prepared. The PCR was performed as follows: 
 Initial denaturation at 98°C for 30 sec   
 98°C for 10 sec 
x 40 cycles  50-72°C for 30 sec 
 72°C for 30 sec per kb 
 Final elongation at 72°C for 10 min   
 
2.2.4. sgRNA design and cloning 
All sgRNAs against the NOP14-AS1, MNX1-AS1, HOTAIR, LINC00441, HOXD1-AS1 and TP53 loci were designed 
using the online tool available at www.crispr.mit.edu. To control for specificity, only those guides were chosen 
which had two or more mismatches to any of the predicted off-targets in the genome114. Sense and antisense 
oligonucleotides corresponding to the sgRNAs (Table 5) were annealed and cloned into PX458 / lentiGuide-
Puro (a gift from Prof. Feng Zhang, obtained through addgene, plasmid #52963) / lentidCas9-KRAB-PURO iv 
sgRNA as described in Ran et al., Nature Protocols, 201392. 
Table 5: Sequences of sgRNAs used in this study 
Name Target Sequence 
Control sgRNA EGFP 5’-GGGCGAGGAGCTGTTCACCGGGG-3’ 
NOP14-AS1 sgRNA#1 NOP14-AS1 5’-GACGGACGGTCGCACAGACGCGG-3’ 
NOP14-AS1 sgRNA#2 NOP14-AS1 5’-AGAGATGTACGTCACTTCCGGGG-3’ 
NOP14-AS1 sgRNA#3 NOP14-AS1 5’-ACAGCCAAGCAGCGACCCGCAGG-3’ 
NOP14-AS1 sgRNA#4 NOP14-AS1 5’-GTCTCGGCCTCGGGGTTACGCGG-3’ 
NOP14-AS1 sgRNA#5 NOP14-AS1 5’-GCCCATGGGTCCGCTCCGCGGGG-3’ 
NOP14-AS1 sgRNA#6 NOP14-AS1 5’-GGTCGCACAGACGCGGAACAGGG-3’ 
NOP14-AS1 sgRNA#7 NOP14-AS1 5’-GGCTGCGCGCTCGGGACGGACGG-3’ 
NOP14-AS1 sgRNA#8 NOP14-AS1 5’-CAGACGCGGAACAGGGCACCAGG-3’ 
NOP14-AS1 sgRNA#9 NOP14-AS1 5’-GGGCACCAGGCACGCCGCCAGGG-3’ 
NOP14-AS1 sgRNA#10 NOP14-AS1 5’-ACCCCGCCACTGACTCCGGCCGG-3’ 
NOP14-AS1 sgRNA#11 NOP14-AS1 5’-GCAGCTCTTCCGCTCCGCTCAGG-3’ 
NOP14-AS1 sgRNA#12 NOP14-AS1 5’-CTCCGCGGGGCAGGCGTCGTGGG-3’ 
NOP14-AS1 US sgRNA NOP14-AS1 5’-AGAGATGTACGTCACTTCCGGGG-3’ 
NOP14-AS1 DS sgRNA NOP14-AS1 5’-AAGTAGGACAAGGCCAACTGTGG-3’ 
TP53 sgRNA#1 TP53 5’-GGGAAGCGTGTCACCGTCGTGG-3’ 
TP53 sgRNA#2 TP53 5’-GCTACCTGCTCCCTGGACGGTGG-3’ 
TP53 sgRNA#3 TP53 5’-GCCAGTCTTGAGCACATGGGAGG-3’ 
TP53 sgRNA#4 TP53 5’-CCTTTGCTTCCTCCGGCAGGCGG-3’ 
TP53 sgRNA#5 TP53 5’-TAGTATCTACGGCACCAGGTCGG-3’ 
HOXD-AS1 sgRNA#1 HOXD-AS1 5’-GGTCGCGACGGCTCTCCTCGGG-3’ 
HOXD-AS1 sgRNA#2 HOXD-AS1 5’-GCGAGGAGCGGCGCGCCGACCGG-3’ 
HOXD-AS1 sgRNA#3 HOXD-AS1 5’-GTGGCGCTGGCCGGCCAATGG-3’ 
LINC00441 sgRNA#1 LINC00441 5’-GCTGGTCGGTGCGCGGGCTGGG-3’ 
LINC00441 sgRNA#2 LINC00441 5’-GCTGGTCGGTGCGCGGGCTGGG-3’ 
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Table 5: Sequences of sgRNAs used in this study 
Name Target Sequence 
LINC00441 sgRNA#3 LINC00441 5’-GTTCCCCACAGACGCCGGCGGG-3’ 
MNX1-AS1 sgRNA#1 MNX1-AS1 5’-GGGCGCACCTGTCACCGTCCCGG-3’ 
MNX1-AS1 sgRNA#2 MNX1-AS1 5’-GCTTAGGACCTCGCGGCGCGGG-3’ 
MNX1-AS1 sgRNA#3 MNX1-AS1 5’-GCCAGCGCCGCGCAACAGCCCGG-3’ 
MNX1-AS1 sgRNA#4 MNX1-AS1 5’-GGAGTATCCACTCCCCGTTGG-3’ 
MNX1-AS1 sgRNA#5 MNX1-AS1 5’-GGTTGCCAGTGCCCGCCGTCCGG-3’ 
HOTAIR sgRNA#1 HOTAIR 5’-GGGCCGCCCTCCTAGTGGTTCGG-3’ 
HOTAIR sgRNA#2 HOTAIR 5’-GAGGGGACGCACGTGTACCTGG-3’ 
HOTAIR sgRNA#3 HOTAIR 5’-GCGGCTCTCGCCTGAGAACTGG-3’ 
NOP14 sgRNA#1 NOP14 5’-GCGGCCCGGCACGTGTCTTA-3’ 
NOP14 sgRNA#2 NOP14 5’-CGTTCGAGGTGAAAGTTAAC-3’ 
 
2.2.5. Cell culture  
NCI-H460 cells were cultured in RPMI medium (Sigma-Aldrich) supplemented with 10% FBS and 1% L-
glutamine at 37°C and 5% CO2 in a humidified chamber. HCT116 TP53(+/+) and HCT116 TP53(-/-) 115 cells were 
cultured in McCoy’s 5A Modified Medium (Sigma-Aldrich) supplemented with 10% FBS and 1% L-glutamine at 
37°C and 5% CO2 in a humidified chamber. A549, HEK293T, MCF7 and HepG2 cells were cultured in Dulbecco’s 
Modified Eagles Medium (DMEM, Sigma-Aldrich) supplemented with 10% FBS and 1% L-glutamine at 37°C and 
5% CO2 in a humidified chamber. Cells were regularly split when they reached 80-90% confluency. Briefly, the 
medium was aspirated and cells were washed with pre-warmed 1X PBS followed by incubation with 0.05% or 
0.25% Trypsin-EDTA solution for 5 min at 37°C and 5% CO2 in a humidified chamber. The cells were 
resuspended in appropriate medium and seeded for further experiments or maintenance. 
2.2.6. Drug treatments 
Etoposide (Topoisomerase II inhibitor, induces DSBs in genomic DNA) (33419-42-0, Cayman Chemical), 
Cisplatin (forms intrastrand crosslinks with purine bases in genomic DNA) (CAS 15663-27-1, Merck Millipore), 
Bleomycin (catalyses single-strand breaks as well as DSBs in genomic DNA) (CAS 9041-93-4, Merck Millipore), 
Doxorubicin (Topoisomerase II inhibitor, induces DSBs in genomic DNA) CAS 25316-40-9, Merck Millipore), 
Carboplatin (forms intrastrand crosslinks with purine bases in genomic DNA) (CAS 41575-94-4, Merck 
Millipore), Nutlin-3 (MDM2 antagonist, stabilizes p53) (CAS 548472-68-0, Sigma-Aldrich) and Actinomycin D 
(Intercalates with genomic DNA, inhibits transcription) (CAS 50-76-0, Sigma-Aldrich) were dissolved in DMSO 
(CAS 67-68-5, AppliChem GmbH) to prepare stock solutions. These were diluted in cell culture media to 
achieve the indicated final drug concentrations. At the indicated time point post drug treatments, cells were 
lysed in TRI reagent for RNA extraction or RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% NP-40, 
0.5% sodium deoxycholate supplemented with protease and phosphatase inhibitors) for protein extraction. 
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2.2.7. Virus production and transduction 
Virus production was performed as described earlier116. Briefly, one day prior to transfection, HEK293T cells 
(4x105 cells / well, in a total of 2 ml media) were seeded in Poly-L-Lysine coated 6-well plates (Greiner Bio-
One). Cells were co-transfected with 1.2 µg lentidCas9-Blast / lentidCas9-KRAB-Blast / lenti EGFP Blast / lenti 
NOP14 Blast / lentidCas9-KRAB-PURO iv sgRNA / lentidCas9-VP160-PURO iv sgRNA / lentiGuide-PURO 
(containing the indicated sgRNA), 0.9 µg psPAX2 (packaging plasmid) and 0.3 µg pMD2.G (envelope plasmid) 
using 6 µl Lipofectamine 2000 (ThermoFisher Scientific) in 200 µl Opti-MEM (ThermoFisher Scientific). 48 hours 
post transfection, the lentivirus-containing medium was filtered using a low protein binding 0.45 µm syringe 
filter (Millipore). 0.5 - 1 ml of the filtered virus along with Polybrene (Final concentration: 8 µg / ml) was then 
added to the indicated cells which were seeded in a 6 well plate one day prior to transduction (1x105 cells / 
well, in a total of 2 ml medium). 24 hours post-transduction, the medium was replaced with 2 µg/ml 
Puromycin (ThermoFisher Scientific) and/or 6 µg/ml Blasticidin (InvivoGen) containing media. For Puromycin 
selection, cells were incubated in Puromycin-containing medium for three days. For Blasticidin selection, cells 
were incubated in Blasticidin-containing medium for six days. Untransduced cells were used to monitor for a 
complete selection. The stable cell lines obtained were used for further experiments. 
2.2.8. siPOOL / siRNA / ASO transfection 
RNA interference (RNAi) was performed as described earlier with some minor modifications117. For HOTAIR 
knockdown using siPOOLs, Hela cells (2x105 cells per well) were reverse transfected with 10 nM (final 
concentration) of siPOOL control or siPOOL HOTAIR (siTOOLs Biotech) using 6 µl RNAiMAX reagent in 6-well 
plates. 48 hours post transfection, cells were lysed in TRI reagent for RNA extraction. For TP53 knockdown 
using siPOOLs, NCI-H460 cells (2x105 cells per well) were reverse transfected with 10 nM (final concentration) 
of siPOOL control or siPOOL TP53 (siTOOLs Biotech) using 6 µl RNAiMAX reagent in 6-well plates. 48 hours post 
transfection, cells were treated with 1 μM Doxorubicin (final concentration) or vehicle control DMSO. 24 hours 
post-treatment, cells were lysed in TRI reagent for RNA extraction or 1XRIPA buffer (50 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 1.0% NP-40 and 0.5% sodium deoxycholate) supplemented with Protease inhibitor (Roche) and 
Phosphatase inhibitor (Roche) cocktails for protein extraction.  
For NOP14 knockdown using siRNAs, NCI-H460 cells (2x105 cells per well) were reverse transfected with 40 nM 
(final concentration) of the control siRNA or two independent siRNAs against NOP14 (Eurofins Genomics) using 
2 µl RNAiMax reagent in 12-well plates. 24 hours post transfection, cells were treated with DMSO or 1 μM 
Doxorubicin (final concentration). 24 hours post-treatment, cells were lysed in TRI reagent for RNA extraction 
or RIPA buffer for protein extraction. 
For NOP14-AS1 knockdown using Antisense LNA GapmeRs (Exiqon), NCI-H460 cells (2x105 cells per well) were 
reverse transfected with 50 nM (final concentration) of the control GapmeR or two independent GapmeRs 
against NOP14-AS1 using 2 µl Dharmafect1 reagent (Dharmacon GE Life Sciences) in 12 well plates. 24 hours 
post transfection, cells were lysed in 1 ml TRI reagent. For MNX1-AS1 knockdown using ASOs (IDT DNA 
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Technologies), NCI-H460 cells (4x105 cells per well) were reverse transfected with 30 nM (final concentration) 
of the control ASO or two independent ASOs against MNX1-AS1 using 4 µl Dharmafect1 reagent in 6-well 
plates. 
For NOP14-AS1 knockdown using Antisense LNA GapmeRs, followed by Doxorubicin treatment experiments, 
NCI-H460 cells (4x105 cells per well) were reverse transfected with 25 nM (final concentration) of the control 
or two independent LNA GapmeRs (Exiqon) against NOP14-AS1 using 6 µl RNAiMAX reagent (ThermoFisher 
Scientific) in 6-well plates. 24 hours post transfection, cells were treated with 1 μM Doxorubicin (final 
concentration) or vehicle control DMSO. 24 hours post-treatment, cells were lysed in TRI reagent for RNA 
extraction or RIPA buffer for protein extraction.  
The sequences of all the siRNAs / antisense oligos can be found in Table 6, whereas the sequences of all the 
individual siRNAs in the siPOOL HOTAIR, as well as siPOOL TP53, can be found in Table 7. 
Table 6: List of siRNAs / antisense oligos used in this study 
Name Target Sequence 
Control LNA Gapmer Control 5’-AACACGTCTATACGC -3’ 
NOP14-AS1 LNA Gapmer#1 NOP14-AS1 5’-AATTCACACCATCTTT -3’ 
NOP14-AS1 LNA Gapmer#2 NOP14-AS1 5’-GAGATCCGCAAGCATT -3’ 
Control ASO Control 5’-GCGTATTATAGCCGATTAAC -3’ 
MNX1-AS1 ASO#1 MNX1-AS1 5’-TGGCCCGCAGGCTAGTGTCT -3’ 
MNX1-AS1 ASO#2 MNX1-AS1 5’-TCACGTAGCACTGTGGCCCG -3’ 
siNOP14(1) NOP14 5’-CCAATCCGTTCGAGGTGAAAGTTAA-3’ 
siNOP14(2) NOP14 5’-GGAAAGAGCTGATTGAAGA-3’ 
 
Table 7: Sequences of individual siRNAs of the siPOOLs used in this study 
siRNA# siPOOL TP53 siPOOL HOTAIR 
1 5'-CACACCCTGGAGGATTTCA-3' 5'-GGGAGTACAGAGAGAATAA-3' 
2 5'-GCTGTCCCTCACTGTTGAA-3' 5'-GCGCCAGACGAAGGTGAAA-3' 
3 5'-GAAGGGTCAACATCTTTTA-3' 5'-CGGCAGTTCCCGGAACAAA-3' 
4 5'-GTCTACCTCCCGCCATAAA-3' 5'-GAGTGCACTGTCTCTCAAA-3' 
5 5'-CTTTTGCATGTTTTGTAGA-3' 5'-GACATAGGAGAACACTTAA-3' 
6 5'-CTGGATGGAGAATATTTCA-3' 5'-GACTTGAGCTGCTCCGGAA-3' 
7 5'-GCCTTGAAACCACCTTTTA-3' 5'-GGAATCCACCTGCCTGTTA-3' 
8 5'-GCATTGTGAGGGTTAATGA-3' 5'-CCTAGACTTAAGATTCAAA-3' 
9 5'-CAAGGCCCATATCTGTGAA-3' 5'-GGGTCCTAGCTCGCCACAT-3' 
10 5'-GCCCACTTCACCGTACTAA-3' 5'-GCCTTTGGAAGCTCTTGAA-3' 
11 5'-CATACCAGCTTAGATTTTA-3' 5'-GCTTGTTAACAAGACCAGA-3' 
12 5'-GGATGGGGAGTAGGACATA-3' 5'-GAGACACATGGGTAACCTA-3' 
13 5'-GTGTGGAGTATTTGGATGA-3' 5'-GCAACCACGAAGCTAGAGA-3' 
14 5'-CAACAAGATGTTTTGCCAA-3' 5'-GCCAAGCACCTCTATCTCA-3' 
15 5'-GATCTCTTATTTTACAATA-3' 5'-GCTGACAGGGTCTGGGACA-3' 
16 5'-GAGGATTTCATCTCTTGTA-3' 5'-GCTCCGCTTCGCAGTGGAA-3' 
17 5'-CACTGTTGAATTTTCTCTA-3' 5'-GCACATTCTGCCCTGATTT-3' 
18 5'-CCCATCCTCACCATCATCA-3' 5'-GGGCCTAAGCCAGTACCGA-3' 
19 5'-GAGGTTGGCTCTGACTGTA-3' 5'-GTCCGTTCAGTGTCAGAAA-3' 
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Table 7: Sequences of individual siRNAs of the siPOOLs used in this study 
siRNA# siPOOL TP53 siPOOL HOTAIR 
20 5'-CTGACAACCTCTTGGTGAA-3' 5'-CGGGACTTTGCACTCTAAA-3' 
21 5'-GCCAAACCCTGTCTGACAA-3' 5'-GGCGCCTTCCTTATAAGTA-3' 
22 5'-CATGGGGTCTAGAACTTGA-3' 5'-GCCCAGAGAACGCTGGAAA-3' 
23 5'-CTCACAGAGTGCATTGTGA-3' 5'-GGAGGCGCTAATTAATTGA-3' 
24 5'-GTTAAGGGTTAGTTTACAA-3' 5'-GCTAAATAGACTCAGGACT-3' 
25 5'-GGGATGTTTGGGAGATGTA-3' 5'-GCAGATGGAGATTACCATT-3' 
26 5'-CACTACAACTACATGTGTA-3' 5'-GGCCTGGGAGTTCCACAGA-3' 
27 5'-CATGAGCGCTGCTCAGATA-3' 5'-CCTTTGCTTCGTGCTGATT-3' 
28 5'-GCTGTGGGTTGATTCCACA-3' 5'-GTAGACCCAGCCCAATTTA-3' 
29 5'-GGTGAACCTTAGTACCTAA-3' 5'-CGGAACCCATGGACTCATA-3' 
30 5'-GTACCACCATCCACTACAA-3' 5'-GAGAAGTGCTGCAACCTAA-3' 
 
2.2.9. RNA extraction  
RNA was isolated using TRI reagent (Sigma-Aldrich) according to the manufacturer’s recommendations with 
some minor modifications. Cells were lysed using 1 ml TRI reagent per well of a 6 well plate. 200 µl Chloroform 
(Carl Roth) was added per ml of lysate, vortexed briefly and centrifuged for 15 minutes at 4oC and 13000g. 
Following phase separation, 500 µl of the aqueous layer was transferred to a new tube and 500 µl Isopropanol 
(Sigma-Aldrich) was added to it. This was gently mixed, incubated at room temperature for 10 min and 
centrifuged for 10 minutes at 4oC and 13000g. The supernatant was discarded and the precipitate was washed 
once with 70% Ethanol (Sigma-Aldrich) followed by centrifugation at 13,000 g for 5 min at 4°C. The 
supernatant was discarded and the precipitate was resuspended in a 50 µl solution containing 1x DNase I 
reaction buffer (Roche) and 1 µl of DNase I (10U/µl; Roche) followed by an incubation for 30 min at 37°C, to 
ensure removal of genomic DNA. 150 µl of nuclease free water was added to the DNAse I treated RNA. 
Thereafter, the RNA was subjected to Phenol: Chloroform extraction to remove any protein contaminations. 
To each tube, 200 µl of Roti-Aqua-P/C/I (Carl Roth) was added, vortexed briefly and centrifuged for 5 minutes 
at 4oC and 13000g. Following phase separation, 200 µl of the aqueous layer was transferred to a new tube and 
200 µl Chloroform (Carl Roth) was added to it. This was again vortexed briefly and centrifuged for 5 minutes at 
4oC and 13000g. 200 µl of the aqueous layer was transferred to a fresh tube and mixed with 20 µl of 3 M 
sodium acetate pH 5.2 (Carl Roth). 500 μl of ice-cold ethanol (Sigma-Aldrich) was added, mixed gently by 
inverting the tube and incubated overnight at -80°C. Following overnight incubation, the RNA solution was 
centrifuged for 10 minutes at 4oC and 13000g. The supernatant was discarded and the precipitate was washed 
once with 70% Ethanol (Sigma-Aldrich) followed by centrifugation at 13,000 g for 5 min at 4°C. The 
supernatant was discarded and the precipitate was resuspended in 20-50 µl nuclease free water. 
2.2.10. Reverse Transcription - quantitative Polymerase Chain Reaction (RT-qPCR) 
A total of 1-2 µg RNA was reverse transcribed to generate cDNA using random hexamer primers and RevertAid 
Reverse Transcriptase (ThermoFisher Scientific) as per the manufacturer’s recommendations. Briefly, a mixture 
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of RNA, 2 µl of dNTP mix (Thermo Fisher Scientific) and 1 µl of Random Hexamer Primer (Thermo Fisher 
Scientific) was prepared in a final volume of 11.5 µl and incubated for 5 min at 65°C. The reaction was 
transferred on ice and 4 µl Reverse Transcriptase buffer, 1 µl RevertAid Reverse Transcriptase (Thermo Fisher 
Scientific). And 0.5 µl RiboLock RNase Inhibitor (Thermo Fisher Scientific) was added. Thereafter, the reaction 
was incubated at 25°C for 10 min, 42°C for 1 h, and 72°C for 10 min. To further control for any residual 
genomic DNA contamination, a minus-RT reaction was also performed where reverse transcriptase was 
replaced by water. The cDNA generated was diluted by a factor of 20 or 40 and RT-qPCR was performed using 
PowerSYBRGreen PCR Master Mix (ThermoFisher Scientific) in a StepOnePlus qPCR instrument (Life 
Technologies). Quantification was performed using the ΔΔCt method and the housekeeping gene PPIA 
(Cyclophilin A) was used for normalization. A final reaction volume of 15 µl containing 7.5 µl Power SYBR Green 
Master Mix, 0.45 µl forward and reverse primer each (10 µM), and 5 µl of pre-diluted cDNA and 1.6 µl water 
was prepared. The qPCR was performed as follows: 
 Initial denaturation at 95°C for 10 min   
 95°C for 15 sec 
x 40 cycles 
 60°C for 30 sec 
 Final elongation at 72°C for 10 min   
The sequences of all RT-qPCR primers can be found in Table 8. 
Table 8: List of primers used for RT-qPCR (F = Froward, R = Reverse) 
Name Target Sequence 
NOP14-AS1 amplicon#1 F NOP14-AS1 5’-CCATGCCCTCCTTGTTTACT-3’ 
NOP14-AS1 amplicon#1 R NOP14-AS1 5’-GGGAAAGGGCTGTTATCATCTT-3’ 
NOP14-AS1 amplicon#2 F NOP14-AS1 5’-CCAGAGGTGCATTTCAGGAT-3’ 
NOP14-AS1 amplicon#2 R NOP14-AS1 5’-AAGGCAGGAAGATTGCTTCA-3’ 
MFSD10 F MFSD10 5’-GTCTACTTCCTCTACCTCTTCCT-3’ 
MFSD10 R MFSD10 5’-CTGCTGTAGGCTACTGAACTG-3’ 
TP53 F TP53 5’-GTGACACGCTTCCCTGGATT-3’ 
TP53 R TP53 5’-TGTTTCCTGACTCAGAGGGG-3’ 
WRAP53α F WRAP53α 5’-CGGAGCCCAGCAGCTACC-3’ 
WRAP53α R WRAP53α 5’-TTGTGCCAGGAGCCTCGCA-3’ 
HOXD-AS1 F HOXD-AS1 5’-TTCATCTGGGAGTTCTTGGCA-3’ 
HOXD-AS1 R HOXD-AS1 5’-GCTGGACCTGGCCTGAAAAT-3’ 
HOXD1 F HOXD1 5’-CGCACGAATTTCAGCACCAA-3’ 
HOXD1 R HOXD1 5’-AGGTGCAAGCAGTTGGCTAT-3’ 
LINC00441 F LINC00441 5’-GGACGTGCTTCTACCCAGAAC-3’ 
LINC00441 R LINC00441 5’-TCCTTCTCAGTTGACGAGTTCA-3’ 
RB1 F RB1 5’-GAGGACCTGCCTCTCGTCAG-3’ 
RB1 R RB1 5’-TCCCAAGTTAACCAAGCTCTCT-3’ 
MNX1-AS1 F MNX1-AS1 5’-CCAAAGCTCTGCAGGTCGAA-3’ 
MNX1-AS1 R MNX1-AS1 5’-GCTGCAGCATTCTGGGAAAAG-3’ 
MNX1 F MNX1 5’-GTTGAGCTTGAACTGGTGCTC-3’ 
MNX1 R MNX1 5’-GATCCTGCCTAAGATGCCCG-3’ 
HOTAIRα F HOTAIR 5’-GACAGAAGGAAAGCCCTCCAG-3’ 
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Table 8: List of primers used for RT-qPCR (F = Froward, R = Reverse) 
Name Target Sequence 
HOTAIRα R HOTAIR 5’-GGTTCCGGAAATCAGGGCAG-3’ 
HOTAIRβ F HOTAIR 5’-GGGGTGTTGGTCTGTGGAAC-3’ 
HOTAIRβ R HOTAIR 5’-CCTGTGCTCTGGAGCTTGAT-3’ 
HOXC11 F HOXC11 5’-GGCTGAGGAGGAGAACACAAA-3’ 
HOXC11 R HOXC11 5’-GTTCCCGGATCTGGAATTTCG-3’ 
NOP14 F NOP14 5’-GAGGTTTGCTCTGGAACAGC-3’ 
NOP14 R NOP14 5’-TCGATGTCTGCCAAAGACTG-3’ 
CDKN1A F CDKN1A 5’-CGAAGTCAGTTCCTTGTGGAG-3’ 
CDKN1A R CDKN1A 5’-CATGGGTTCTGACGGACAT-3’ 
CyclophilinA F Cyclophilin A 5'-GTCAACCCCACCGTGTTCTT-3’ 
CyclophilinA R Cyclophilin A 5'-CTGCTGTCTTTGGGACCTTGT-3’ 
 
2.2.11. Western Blot 
Protein lysates were prepared as described earlier with some minor modifications118. Briefly, cells were rinsed 
with ice-cold phosphate-buffered saline (PBS, Sigma-Aldrich) and incubated for 30 min on ice in 200 µl RIPA 
buffer per well of a 6-well plate. Following lysis, the crude lysate was subjected to centrifugation for 30 min at 
4oC and 17000g to precipitate cellular debris. The protein concentration was determined using the BCA assay 
and equal amounts (10 µg / 20 μg) of lysates were separated on self-cast 10% SDS-PAGE gels and transferred 
to Nitrocellulose membranes. The membranes were blocked using 5% milk in TBST (50 mM Tris, 150 mM NaCl, 
0.05% Tween 20) and then incubated with primary antibodies according to the manufacturer’s 
recommendations. The following primary antibodies were used: NOP14 (#HPA039596, Sigma-Aldrich), TP53 
(#554293, BD Pharmingen) RB1 (#554136, BD Pharmingen), TP53 (#554293, BD Pharmingen / sc-126, Santa 
Cruz Biotechnology), PARP (#9542, Cell Signaling Technology) and GAPDH (#MAB374, EMD Millipore). 
Following incubation with the primary antibody, the membranes were washed with TBST and incubated with 
secondary antibodies which were either HRP-coupled (Dianova) or NIR-fluorescent reagent (LI-COR IRDye® 
800CW) conjugated. Chemiluminescence detection was performed using Super Signal West Pico 
chemiluminescent substrate (ThermoFisher Scientific) or Super Signal™ West Femto chemiluminescent 
substrates on a ChemoCam Imager (Intas). Fluorescence detection was performed using LI-COR Biosciences 
Odyssey®. Image Studio™ Lite was used for image analysis and band quantification. 
2.2.12. 5’- and 3’-RACE 
RNA was extracted from HepG2 cells treated with 50 μM Etoposide for 16h and reverse transcribed using the 
SMARTer RACE cDNA Amplification Kit (Clontech) according to manufacturer’s instructions. 5’- and 3’- RACE 
PCR products were generated using Advantage 2 PCR Enzyme System (Clontech) according to the 
manufacturer’s instructions. The gene-specific primers used for 5’-and 3’-RACE can be found in Table 4. The 
PCR products obtained were gel eluted and cloned into the pCR2.1-TOPO vector using the TOPO TA cloning kit 
(ThermoFisher Scientific) and sequenced using the M13 reverse primer. Alignment of the RACE sequences to 
the UCSC genome browser was performed using BLAT tool119.  
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3. Results 
3.1. CRISPRi as a tool for knockdown of lncRNA genes 
Loss-of-function models are indispensable for dissecting gene function. Prior to the advent of RNAi, generation 
of loss-of-function models required painstaking work and often relied on chance mutations in the genes of 
interest. Over the past few decades, RNAi has greatly facilitated generation of such models. However, when it 
comes to lncRNA research, RNAi has several limitations: (1) RNAi machinery is mainly cytoplasmic, making it 
difficult to target the nuclear fraction of lncRNAs120, 121, (2) siRNAs are often inefficient in targeting RNAs with 
strong secondary structures, which is often the case for lncRNAs122, (3) barring a few exceptions123, the RNAi 
machinery acts post-transcriptionally and thus cannot uncover phenotypes arising as a result of the act of 
lncRNA transcription. 
Antisense oligos (ASOs) offer an orthogonal technique to knockdown lncRNA expression124. ASOs do not rely 
on the RNAi machinery and instead guide the endogenous RNase H to their target in a sequence-specific 
manner. Unlike RNAi, ASOs can efficiently target nuclear RNAs and can also target nascent transcripts, making 
them suitable to study transcript-dependent in cis effects121, 125, 126. However, they cannot inhibit transcription 
and their short-lived knockdown efficiencies as well as the associated toxicity, make them an inferior tool for 
the generation of loss-of-function model. 
CRISPR/Cas9 has recently emerged as a powerful tool for genome editing. As explained earlier, Cas9 can be 
used for lncRNA manipulation in several ways: Cas9 can be used to either delete promoter or the entire body 
of a lncRNA gene. It can also be used to knockin RNA destabilizing elements to knockdown lncRNA expression. 
Lastly, dCas9-based custom transcription factors can be used to modulate lncRNA transcription without 
altering its genomic sequence. All these approaches can overcome the limitations imposed by RNAi/ASO-based 
lncRNA knockdown. However, Cas9 based deletion approaches for lncRNA knockout can lead to simultaneous 
deletion of underlying genomic elements and thus assign false phenotypes to the lncRNA gene targeted. Also, 
these approaches involve time-consuming clonal selection. CRISPRi-mediated lncRNA knockdown promises to 
overcome these problems as dCas9 ordCas9-KRAB do not alter the genomic sequence, but inhibit the 
transcription of the lncRNA. 
3.1.1. NOP14-AS1 knockdown using CRISPRi affects MFSD10 expression 
To study the in cis-regulatory effects of NOP14-AS1 lncRNA on the expression of NOP14 mRNA, a loss-of-
function model was required. Given the limitations of RNAi- and ASO-based approaches for lncRNAs, it was 
proposed to utilize CRISPR/Cas9 instead. A CRISPRi-based knockdown of NOP14-AS1 from its endogenous 
promoter would be able to reverse the NOP14-AS1 transcript- or its transcription-dependent effects on the 
expression of NOP14 mRNA.  
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Five different sgRNAs spanning the NOP14-AS1 promoter were designed (Figure 7A). sgRNA#1 and sgRNA#2 
were designed upstream of the NOP14-AS1 TSS whereas sgRNA#3 to sgRNA#5 were designed downstream of 
the NOP14-AS1 TSS with the aim of identifying at least two sgRNAs that could repress NOP14-AS1 expression. 
These sgRNAs were introduced into NCI-H460 cells expressing dCas9 (without an inhibitory domain) and 
expression of NOP14-AS1 and MFSD10 were monitored. Since NOP14-AS1 arises from the bidirectional 
promoter of MFSD10, it was necessary to monitor the MFSD10 expression as it was possible that dCas9 could 
also target its expression which would be indistinguishable from effects of NOP14-AS1 knockdown on MFSD10 
expression via earlier described in cis-regulatory mechanisms. 
Expression of these sgRNAs in NCI-H460 cells expressing dCas9 (without an inhibitory domain), did not yield in 
an efficient knockdown of NOP14-AS1 (Figure 7B,C). sgRNA#4 and sgRNA#5 showed a minor repression of 
NOP14-AS1 (as detected using amplicon #1 only), but did not affect MFSD10 expression (Figure 7D). sgRNA#1, 
which bound a region immediately downstream of the MFSD10 TSS, strongly repressed its expression without 
affecting NOP14-AS1 indicating that this sgRNA targeted the core promoter of MFSD10. Several other sgRNAs 
targeting the promoter of NOP14-AS1 were also designed and tested in combination with dCas9, but they 
failed to efficiently knockdown NOP14-AS1 expression (Supplementary Figure 33). These results showed that 
dCas9 alone was not a potent inhibitor of transcription unless it was targeted to the core promoter. 
On the other hand, introduction of these five sgRNAs into NCI-H460 cells expressing dCas9-KRAB resulted in 
strong repression of the intended target NOP14-AS1 for three out of five of these sgRNAs (sgRNA#1, sgRNA#3 
and sgRNA#5) (Figure 7A,B) indicating that dCas9-KRAB could be used to efficiently repress lncRNA 
transcription from their endogenous promoter. However, MFSD10 expression was also affected by all sgRNAs 
which repressed NOP14-AS1 expression (Figure 7D). To determine whether the simultaneous knockdown of 
MFSD10 and NOP14-AS1 using dCas9-KRAB was due to an endogenous cis-regulatory mechanism or was an 
artifact of this technique, antisense LNA GapmeRs were used to knockdown expression of the lncRNA NOP14-
AS1. Knockdown of NOP14-AS1 using two independent antisense LNA GapmeRs reduced the expression of 
NOP14-AS1 (Figure 7E). In contrast to the results from a dCas9-KRAB-mediated knockdown, MFSD10 
expression was unchanged or even slightly induced upon NOP14-AS1 knockdown using antisense LNA 
GapmeRs (Figure 7E) indicating that the observed reduction of MFSD10 expression upon NOP14-AS1 
knockdown using dCas9-KRAB was not as a result of reduced NOP14-AS1 lncRNA transcript. However, since 
ASOs cannot inhibit transcription, it could not be ruled out that dCas9-KRAB-mediated repression of NOP14-
AS1 transcription could affect MFSD10 expression in cis. 
To further clarify whether this dCas9-KRAB-mediated simultaneous knockdown of the neighboring gene from a 
proximal promoter along with the intended target was restricted to the MFSD10/NOP14-AS1 locus, or was a 
widespread phenomenon, it was decided to test this system for knockdown of other similarly located 
lncRNA/mRNA gene pairs.  
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Figure 7: NOP14-AS1 and MFSD10 gene modulation using CRISPRi and antisense LNA GapmeRs 
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A: Schematic representation of the MFSD10/NOP14-AS1 genomic locus depicting the sgRNAs and LNA antisense 
GapmeRs used to target NOP14-AS1 as well as the RT-qPCR amplicons used to detect its expression. 
B-D: NCI-H460 cells expressing either dCas9 or dCas9-KRAB were transduced with either a control sgRNA or one of the 
five indicated sgRNAs targeting the NOP14-AS1 promoter. RT-qPCR results for (B) NOP14-AS1 amplicon #1, (C) NOP14-
AS1 amplicon #2 and (D) MFSD10 normalized to Cyclophilin A and control sgRNA. Error bars represent SD (n≥4). * 
p<0.05; ** p<0.01; *** p<0.001 compared to dCas9/dCas9-KRAB + control sgRNA, unpaired two-sided t-test. 
E: NCI-H460 cells were transfected with either a control or two independent antisense LNA GapmeRs against NOP14-
AS1. RT-qPCR results for NOP14-AS1 amplicon#1, amplicon#2 and MFSD10 normalized to Cyclophilin A and control 
antisense LNA GapmeR. Error bars represent SD (n=4). * p<0.05; ** p<0.01; *** p<0.001 compared to control 
GapmeR, unpaired two-sided t-test. 
Data used here has been published as a part of the following manuscript: Goyal et al., Nucleic Acids Res, 2016116. 
 
 
3.1.2. TP53 knockdown using CRISPRi affects WRAP53α expression 
Similar to the MFSD10/NOP14-AS1 locus, the well-known tumor suppressor gene TP53 (p53) is also transcribed 
in a bidirectional fashion, partially overlapping with another protein-coding gene (WRAP53) in a head-to-head 
antisense orientation. WRAP53 is expressed from three different TSSs, namely α, β, and γ. The α-TSS lies 
roughly 100 bp downstream of the TP53 TSS overlapping with its first exon (Figure 8A). The transcript arising 
from this TSS (WRAP53α) does not code for a protein but is known to bind to TP53 mRNA via sense-antisense 
base pairing and regulate TP53 mRNA stability, expression and is also required for TP53 induction upon DNA 
damage43. Since TP53 is one of the most widely characterized genes and this locus is another example of a 
bidirectional promoter, it was decided to knockdown TP53 expression using dCas9/dCas9-KRAB as well as an 
siPOOL (a pool of 30 defined siRNAs with non-identical seed regions to minimize any potential off-target 
effects127) to compare the effects on WRAP53α expression. 
Similar to NOP14-AS1, five different sgRNAs distributed across the TP53 promoter were designed to target 
TP53 expression. sgRNA#1, sgRNA#2 and sgRNA#3 were designed downstream of the TP53 TSS whereas 
sgRNA#4 and sgRNA#5 were designed upstream of the TP53 TSS (Figure 8A). When these sgRNAs were 
introduced into dCas9 expressing NCI-H460 cells, sgRNA#1 and sgRNA#2 resulted in TP53 mRNA as well as 
protein knockdown (Figure 8B,C,D). Both of these sgRNAs also resulted in WRAP53α knockdown (Figure 8E). 
When these sgRNAs were introduced into dCas9-KRAB expressing NCI-H460 cells, all sgRNAs led to a significant 
repression of TP53 mRNA and protein expression to varying extents (Figure 8B,C,D) indicating once again that 
dCas9-KRAB was a more potent inhibitor of transcription as compared to dCas9 alone. More importantly, all 
sgRNAs strongly affecting TP53 expression also had a strong impact on WRAP53α expression except for 
sgRNA#1 which displayed a non-significant trend (Figure 8E). 
In contrast to the results from a dCas9-/dCas9-KRAB-mediated knockdown, RNAi-mediated silencing of TP53 
using an siPOOL resulted in a strong downregulation of TP53 mRNA as well as protein but had no effect on 
WRAP53α expression (Figure 9). Thus, dCas9-/dCas9-KRAB-mediated targeting of bidirectional promoters 
again led to a repression of both genes in the locus.  
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Figure 8: TP53 knockdown using CRISPRi  
A: Schematic representation of the TP53 / WRAP53α genomic locus depicting the sgRNAs used to target TP53 as well 
as the RT-qPCR amplicons used to detect TP53 and WRAP53α expression. 
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B-D: NCI-H460 cells expressing either dCas9 or dCas9-KRAB were transduced with either a control sgRNA or one of 
five indicated sgRNAs targeting TP53. (B) RT-qPCR results for TP53 normalized to Cyclophilin A and control sgRNA. 
Error bars represent SD (n=4). * p<0.05; ** p<0.01; *** p<0.001 compared to dCas9/dCas9-KRAB + control sgRNA, 
unpaired two-sided t-test. (C) Western blot results for p53. GAPDH was used as loading control. (D) Quantification of 
the p53 expression normalized to GAPDH and control sgRNA. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** 
p<0.001 compared to dCas9/dCas9-KRAB + control sgRNA, unpaired two-sided t-test. (E) RT-qPCR results for 
WRAP53α normalized to Cyclophilin A and control sgRNA. Error bars represent SD (n=4). * p<0.05; ** p<0.01; *** 
p<0.001 compared to dCas9/dCas9-KRAB + control sgRNA, unpaired two-sided t-test. 
Data used here has been published as a part of the following manuscript: Goyal et al, NAR, 2016116 
 
 
 
Figure 9: TP53 knockdown using an siPOOL 
NCI-H460 cells were transfected with either a control siPOOL or an siPOOL targeting TP53. (A) RT-qPCR results for 
TP53 and WRAP53α normalized to Cyclophilin A and siPOOL control. Error bars represent SD (n=6). * p<0.05; ** 
p<0.01; *** p<0.001 compared to siPOOL control, unpaired two-sided t-test. (B) Western blot results for p53. GAPDH 
was used as loading control. (C) Quantification of the p53 expression normalized to GAPDH and control siPOOL. Error 
bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control siPOOL, unpaired two-sided t-test.  
Data used here has been published as a part of the following manuscript: Goyal et al., Nucleic Acids Res, 2016116. 
 
 
3.1.3. HOXD-AS1 knockdown using dCas9-KRAB affects HOXD1 expression 
As another example of a lncRNA arising from a bidirectional promoter, HOXD-AS1 was selected. HOXD-AS1 is a 
lncRNA encoded in the HOXD locus and similarly to NOP14-AS1, HOXD-AS1 also arises from the bidirectional 
promoter shared with a protein-coding gene, HOXD1. HOXD-AS1 knockdown using siRNAs was shown to have 
no impact on HOXD1 expression. Three different sgRNAs spanning the HOXD-AS1 promoter were designed 
(Figure 10A) and expressed in A549 cells along with dCas9-KRAB. All three sgRNAs resulted in strong 
repression of HOXD-AS1 as well as HOXD1 (Figure 10B,C). 
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Figure 10: HOXD-AS1 knockdown using dCas9-KRAB 
A: Schematic representation of the HOXD1 / HOXD-AS1 genomic locus depicting the sgRNAs used to target HOXD-AS1 
as well as the RT-qPCR amplicons used to detect HOXD1 and HOXD-AS1 expression. 
B,C: A549 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either control sgRNA or one of the 
three indicated sgRNAs targeting HOXD-AS1. RT-qPCR results for (B) HOXD1-AS1 and (C) HOXD normalized to 
Cyclophilin A and control sgRNA. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control 
sgRNA, unpaired two-sided t-test. 
Data used here has been published as a part of the following manuscript: Goyal et al., Nucleic Acids Res, 2016116. 
 
 
3.1.4. LINC00441 knockdown using dCas9-KRAB affects RB1 expression 
LINC00441 arises from the bidirectional promoter shared with the tumor suppressor gene RB1 and its 
knockdown using siRNAs in A549 cells did not impact RB1 expression128. However, dCas9-KRAB-mediated 
knockdown of LINC00441 using three independent sgRNAs targeting its promoter strongly reduced RB1 mRNA 
as well as protein expression in these cells (Figure 11A-D).  
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Figure 11: LINC00441 knockdown using dCas9-KRAB 
A: Schematic representation of the RB1 / LINC00441 genomic locus depicting the sgRNAs used to target LINC00441 
and the RT-qPCR amplicons used to detect RB1 and LINC00441 expression. 
B-D: A549 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either a control sgRNA or one of the 
three indicated sgRNAs targeting LINC00441. (B) RT-qPCR results for RB1 and LINC00441 normalized to Cyclophilin A 
and Control sgRNA. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, 
unpaired two-sided t-test. (C) Western blot results for RB1. GAPDH was used as loading control. (D) Quantification of 
the RB1 protein expression normalized to GAPDH and control sgRNA. Error bars represent SD (n=3). * p<0.05; ** 
p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test.  
Data used here has been published as a part of the following manuscript: Goyal et al., Nucleic Acids Res, 2016116. 
 
 
3.1.5. MNX1-AS1 knockdown using dCas9-KRAB affects MNX1 expression 
LncRNA MNX1-AS1 arises from the bidirectional promoter of MNX1. A dCas9-KRAB-mediated knockdown of 
MNX1-AS1 using five independent sgRNAs targeting its promoter led to knockdown of both MNX1-AS1 as well 
as its neighboring mRNA MNX1 (Figure 12A,B). On the other hand, MNX1-AS1 knockdown using two 
independent ASOs reduced MNX1-AS1 expression without affecting MNX1 expression (Figure 12C). 
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Figure 12: MNX1-AS1 gene modulation using dCas9-KRAB and ASOs 
A: Schematic representation of the MNX1/MNX1-AS1 genomic locus depicting the sgRNAs and antisense oligos used 
to target MNX1-AS1 as well as the RT-qPCR amplicons used to detect MNX1 and MNX1-AS1 expression. 
B: NCI-H460 cells expressing dCas9-KRAB were transduced with either a control sgRNA or one of the five indicated 
sgRNAs targeting MNX1-AS1. RT-qPCR results for MNX1 and MNX1-AS1 normalized to Cyclophilin A and control 
sgRNA. Error bars represent SD (n=4). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-
sided t-test. 
C: NCI-H460 cells were transfected with either a control ASO or two independent ASOs against MNX1-AS1. RT-qPCR 
results for MNX1 and MNX1-AS1 normalized to Cyclophilin A and control ASO. Error bars represent SD (n=4). * p<0.05; 
** p<0.01; *** p<0.001 compared to control ASO, unpaired two-sided t-test. 
Data used here has been published as a part of the following manuscript: Goyal et al., Nucleic Acids Res, 2016116. 
 
3.1.6. HOTAIR knockdown using dCas9-KRAB affects HOXC11 expression 
HOTAIR is a 2.2 kilobase pair (kb) long lncRNA that is transcribed in an antisense direction to the HOXC gene 
cluster and recruits the PRC2 complex to silence the expression of the HOXD locus in trans30, 129. HOTAIR is 
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expressed from two different TSSs. The α-TSS lies inside the intron of the HOXC11, separated from its TSS by 
roughly 1.8 kb. The β-TSS lies roughly 4 kb upstream of the HOXC11 TSS and accounts for the majority of 
HOTAIR transcription (Figure 13A). HOTAIR deletion was previously shown to have no impact on HOXC11 
expression130. HOTAIR knockdown using an siPOOL targeting HOTAIR also had no impact on the HOXC11 
expression. Since HOTAIRβ and HOTAIRα have common exons, they were both knocked down upon siPOOL 
treatment (Figure 13B). dCas9-KRAB-mediated targeting of the α-TSS using three independent sgRNAs led to a 
very strong knockdown of HOTAIRα expression (Figure 13C). However, no such repression was observed for 
HOTAIRβ indicating that dCas9-KRAB specifically represses transcription from the α-TSS without affecting the 
β-TSS. Importantly, simultaneous to the HOTAIRα knockdown, HOXC11 was also repressed in these cells 
(Figure 13C). Thus, the HOXC11 TSS which was nearly 1.8 kb upstream from the HOTAIRα TSS was repressed 
while targeting the HOTAIRα TSS, whereas the HOTAIRβ TSS, which was 4 kb upstream from the HOTAIRα TSS 
was unaffected.  
 
Figure 13: HOTAIR gene modulation using dCas9-KRAB and siPOOL 
A: Schematic representation of the HOXC11 / HOTAIR genomic locus depicting the sgRNAs used to target HOTAIRα as 
well as the RT-qPCR amplicons used to detect HOXC11 and HOTAIR expression. 
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B: Hela cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either control sgRNA or one of the 
three indicated sgRNAs targeting HOTAIRα. RT-qPCR results for HOXC11, HOTAIRα, and HOTAIRβ normalized to 
Cyclophilin A and control sgRNA. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control 
sgRNA, unpaired two-sided t-test. 
C: Hela cells were transfected with either siPOOL control or siPOOL HOTAIR. RT-qPCR results for HOXC11, HOTAIRα, 
and HOTAIRβ normalized to Cyclophilin A and siPOOL control. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** 
p<0.001 compared to siPOOL control, unpaired two-sided t-test. 
Data used here has been published as a part of the following manuscript: Goyal et al., Nucleic Acids Res, 2016116. 
 
In summary, these results indicated that dCas9-KRAB could simultaneously repress transcription from proximal 
promoter apart from its intended target advocating for caution while using CRISPRi to target lncRNAs as well 
as protein-coding genes. However, given that the NOP14 promoter is more than 28 kb downstream of the 
NOP14-AS1 promoter, this should not prohibit the use of dCas9-KRAB to knockdown NOP14-AS1 expression 
and study its impact on NOP14 expression. 
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3.2. NOP14-AS1 and its impact on NOP14 expression in DNA damage 
3.2.1. Characterization of NOP14-AS1 in DNA damage 
Before the beginning of this dissertation project, lncRNA NOP14-AS1 had already been identified to be induced 
in A549 as well as HepG2 cells upon treatment with DNA damaging drugs Etoposide, Cisplatin and Bleomycin 
using microarray expression analysis. In order to independently validate the results obtained from this 
microarray analysis, an RT-qPCR analysis was performed. NOP14-AS1 along with the well-known p53 target 
gene CDKN1A131 (p21) was induced in this RT-qPCR analysis further validating the results from the microarray 
analysis (Figure 14). 
 
Figure 14: RT-qPCR validation of the microarray analysis 
A549 and HepG2 cells were treated with 50 μM Etoposide (ETO) / 50 μM Cisplatin (CIS) / 20 μM Bleomycin (BLEO) or 
vehicle control DMSO for 8 hours. RT-qPCR results for (A) NOP14-AS1 and (B) CDKN1A normalized to Cyclophilin A and 
DMSO controls. Error bars represent SD (n=4). * p<0.05; ** p<0.01; *** p<0.001 compared to DMSO control, 
unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
Analysis of the NOP14-AS1 genomic loci in the UCSC genome browser132 revealed that it could give rise to 
several splice isoforms (Figure 15, GENCODE transcripts). To establish the full-length sequence of NOP14-AS1, 
cDNA was extracted from HepG2 cells treated with Etoposide and was subjected to 5’- and 3’- Rapid 
Amplification of cDNA Ends (RACE). This analysis could detect most of the previously annotated NOP14-AS1 
splice isoforms as well as several novel variants (Figure 15, 5_RACE and 3_RACE). Moreover, these isoforms 
were 5’-m7G capped and 3’-polyadenylated as the applied RACE protocol could only detect such RNAs133. This 
was corroborated by publically available CAGE and polyA+ RNA-Seq data for several cell lines (Figure 15)134, 135. 
Based on the results from RACE analysis, it was decided to use an RT-qPCR amplicon (Amplicon #2) which 
detected all the variants of NOP14-AS1 for the subsequent experiments (Figure 15). 
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Figure 15: Rapid amplification of cDNA ends identifies NOP14-AS1 splice isoforms 
HepG2 cells were treated with 50 μM Etoposide for 16 hours. cDNA from these cells were subjected to 5’ and 3’ RACE 
for NOP14-AS1. Sanger sequencing results of the clones obtained from 5’ RACE (in green) and 3’ RACE (in blue) 
reactions aligned to the NOP14-AS1 genomic locus in UCSC genome browser. Gencode-annotated transcripts are 
depicted in red. Strand-specific polyA+ RNA seq as well CAGE data (only + strand data shown here) for the indicated 
cell lines was obtained from ENCODE data portal on UCSC genome browser (http://genome.ucsc.edu). RT-qPCR 
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amplicon used in this dissertation is also shown. All alignments were made to GRCh37/hg19 assembly and were 
performed using the UCSC Blat tool119. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
To identify additional cell line models and to investigate the drug-specific strengths of NOP14-AS1 induction, 
four different cell lines were treated with a panel of five DNA damage-inducing reagents of clinical relevance. 
All cell lines showed DNA damage-specific induction of NOP14-AS1. Overall NCI-H460 (Lung Cancer cell line) 
showed the strongest induction of NOP14-AS1. Also, Etoposide and Doxorubicin (both inhibit Topoisomerase II 
and induce DSBs) were the strongest inducers of NOP14-AS1 (Figure 16A). CDKN1A served as a positive control 
to check for functional induction of the DDR in these cells (Figure 16B). Based on these results, it was decided 
to use A549 and NCI-H460 (both lung cancer cell lines) in combination with Etoposide and Doxorubicin as the 
model system to study the role of NOP14-AS1 in the DDR. 
 
Figure 16: Etoposide and Doxorubicin are the strongest inducers of NOP14-AS1 
A549 / HepG2 / NCI-H460 / Hek293 cells were treated with 50 μM Etoposide (ETO) / 50 μM Cisplatin (CIS) / 20 μM 
Bleomycin (BLEO) / 1 μM Doxorubicin (DOXO) / 20 μM Carboplatinum (CARBO) or vehicle control DMSO for 8 hours. 
RT-qPCR results for (A) NOP14-AS1 and (B) CDKN1A normalized to Cyclophilin A and DMSO controls. Error bars 
represent SD (n≥3). * p<0.05; ** p<0.01; *** p<0.001 compared to DMSO control, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
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To uncover the mechanism of NOP14-AS1 induction upon DNA damage, A549 cells were simultaneously 
treated with the transcriptional inhibitor Actinomycin D (ActD) as well as Doxorubicin. Transcriptional 
inhibition resulted in a loss of Doxorubicin-dependent NOP14-AS1 induction, indicating that a transcriptional 
response gave rise to elevated NOP14-AS1 levels upon DNA damage (Figure 17A). CDKN1A, which is known to 
be transcriptionally induced upon DNA damage in a p53-dependent manner131, was used as a positive control 
for this experiment (Figure 17B). 
 
Figure 17: NOP14-AS1 induction upon DNA damage is a transcriptional response 
A549 cells were treated with 1 μM Doxorubicin (DOXO) and either 10 μg/ml ActD or vehicle control DMSO. RT-qPCR 
results for (A) NOP14-AS1 and (B) CDKN1A normalized to Cyclophilin A and untreated controls. Error bars represent 
SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to untreated controls, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
Since the transcription factor p53 is responsible for activating several other lncRNAs involved in the DDR 
pathway51-54, it was hypothesized that NOP14-AS1 induction upon DNA damage could be p53-dependent. 
Nutlin-3 inhibits the interaction between MDM2 and p53 thereby stabilizing p53 and resulting in activation of 
p53 target genes136. Treatment of A549, NCI-H460, and HepG2 cells (p53 wild-type) with the MDM2 antagonist 
Nutlin-3 resulted in NOP14-AS1 induction (Figure 18A). CDKN1A as a known p53 target gene was also induced 
upon Nutlin-3 treatment indicating the activation of p53 in these cells (Figure 18B). The TP53 (-/-) HCT-116 
colon cancer cell line is a frequently used p53 loss-of-function model with the parental TP53 (+/+) HCT-116 cell 
line serving as the control. NOP14-AS1 was upregulated in TP53 (+/+) HCT-116 cells upon treatment with 
Etoposide, Doxorubicin or Nutlin-3. However, this induction was not observed in TP53 (-/-) HCT-116 cells 
(Figure 18C). The p53 target gene CDKN1A served as a positive control (Figure 18D). Furthermore, TP53 
knockdown using dCas9-KRAB or siPOOL abrogated the NOP14-AS1 induction upon Doxorubicin treatment in 
NCI-H460 cells (Figure 22A,E) suggesting that NOP14-AS1 upregulation upon DNA damage induction was p53-
dependent.  
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Figure 18: NOP14-AS1 induction upon DNA damage is p53-dependent 
A,B: A549 / NCI-H460 / HepG2 cells were treated with either 10 μM Nutlin-3 or vehicle control DMSO for 24 hours. 
RT-qPCR results for (A) NOP14-AS1 and (C) CDKN1A normalized to Cyclophilin A and DMSO controls. Error bars 
represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to DMSO controls, unpaired two-sided t-test. 
C,D: HCT116 TP53 WT / TP53 Null cells were treated with 50 μM Etoposide (ETO) / 1 μM Doxorubicin (DOXO) / 10 μM 
Nutlin-3 or vehicle control DMSO for 12 hours. RT-qPCR results for (C) NOP14-AS1 and (D) CDKN1A normalized to 
Cyclophilin A and DMSO controls. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to DMSO 
controls, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
3.2.2. NOP14-AS1 and NOP14 are inversely regulated upon DNA damage 
NOP14-AS1 is transcribed divergently from a bidirectional promoter of the protein-coding gene MFSD10 and 
overlaps with its antisense protein-coding gene NOP14 (Figure 19A). Divergent and antisense transcripts often 
mediate their function by regulating the expression of their neighboring genes in cis19, 109, 137. To check whether 
MFSD10 or NOP14 were regulated upon DNA damage induction, a time-course expression analysis of these 
genes in NCI-H460 cells treated with Doxorubicin was performed. NOP14-AS1 expression gradually increased 
and peaked at 24 hours post-Doxorubicin treatment, thereafter gradually decreasing (Figure 19B). Inversely to 
NOP14-AS1, NOP14 mRNA levels gradually decreased reaching a minimum at 16 hours, thereafter gradually 
increasing to reach basal levels again at 48 hours (Figure 19B). NOP14 protein expression was also reduced 
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reaching a minimum at 36 hours, thereafter showing a slight increase at 48 hours (Figure 19C,D). This analysis 
revealed a strong and statistically significant negative correlation between NOP14-AS1 and NOP14 mRNA 
(Pearson correlation = -0.848, p-value = 0.016) as well as protein expression (Pearson correlation = -0.851, p-
value = 0.015) upon DNA damage induction. On the other hand, MFSD10 expression was unchanged upon 
doxorubicin treatment and only a non-significant positive correlation was observed between NOP14-AS1 and 
MFSD10 mRNA expression (Pearson correlation = 0.495, p-value = 0.259) (Figure 19E). No inferences could be 
drawn for MFSD10 protein expression as it was undetectable using two independent antibodies.  
 
Figure 19: NOP14-AS1 and NOP14 are inversely co-regulated upon DNA damage in NCI H460 cells 
A: NOP14-AS1 genomic locus as depicted in UCSC genome browser. The NOP14-AS1 gene is divergently expressed 
from its upstream neighbor, the MFSD10 gene, and overlapping tail-to-tail with the antisense NOP14 gene.  
42 
 
B-E: NCI-H460 cells were treated with 1 μM Doxorubicin for the indicated time points. (B) RT-qPCR results for NOP14-
AS1 and NOP14 normalized to Cyclophilin A and untreated control. Error bars represent SD (n=4). * p<0.05; ** p<0.01; 
*** p<0.001 compared to untreated control, unpaired two-sided t-test. (C) Western blot results for p53 and NOP14. 
GAPDH was used as a loading control. (D) Quantification of the NOP14 protein expression normalized to GAPDH and 
untreated control. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to untreated control, 
unpaired two-sided t-test. (E) RT-qPCR results for NOP14-AS1 (same as Figure 19B, data given for comparison) and 
MFSD10 normalized to Cyclophilin A and untreated control. Error bars represent SD (n≥3). * p<0.05; ** p<0.01; *** 
p<0.001 compared to untreated control, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
To further corroborate the Doxorubicin-induced inverse co-regulation observed in NCI-H460 between NOP14-
AS1 and NOP14, time-course expression analyses of these genes in NCI-H460 cells treated with Etoposide and 
Cisplatin were performed. Etoposide induced similar changes in expression for NOP14-AS1 as well as NOP14 as 
were observed upon Doxorubicin treatment (Pearson correlation = -0.875, p-value = 0.01) (Figure 20A). 
Treatment with Cisplatin, on the other hand, resulted in a gradual increase of NOP14-AS1 expression peaking 
at 48 hours post treatment, which was the end point of this analysis (Figure 20B). Strikingly, NOP14 expression 
gradually decreased and reached a minimum at 48 hours post treatment (Pearson correlation = -0.647, p-value 
= 0.116). 
 
Figure 20: Etoposide- / Cisplatin-induced inverse co-regulation of NOP14-AS1 and NOP14 in NCI-H460 cells 
A,B: NCI-H460 cells were treated with (A) 50 μM Etoposide or (B) 50 μM Cisplatin for the indicated time points. RT-
qPCR results for NOP14-AS1 and NOP14 normalized to Cyclophilin A and untreated control. Error bars represent SD 
(n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to untreated control, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
The inverse co-regulation of the sense-antisense pair of NOP14 and NOP14-AS1 upon DNA damage induction 
was not restricted to NCI-H460 cells. A time-course expression analysis of these genes in A549 cells treated 
with Doxorubicin or Etoposide also revealed inverse co-regulation between them (Pearson correlation = -
0.810, p-value = 0.027 for Doxorubicin time course; Pearson correlation = -0.616, p-value = 0.140 for Etoposide 
time course) (Figure 21A,B). A time-course expression analysis of these genes in HepG2 cells treated with 
Doxorubicin or Etoposide again revealed an inverse co-regulation between them (Pearson correlation = -0.740, 
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p-value = 0.092 for Doxorubicin time course; Pearson correlation = -0.538, p-value = 0.270 for Etoposide time 
course) (Figure 21C,D). 
 
Figure 21: NOP14-AS1 and NOP14 are inversely co-regulated upon DNA damage in A549 and HepG2 cells 
A,B: A549 cells were treated with (A) 1 μM Doxorubicin or (B) 50 μM Etoposide for the indicated time points. RT-qPCR 
results for NOP14-AS1 and NOP14 normalized to Cyclophilin A and untreated control. Error bars represent SD (n=3). * 
p<0.05; ** p<0.01; *** p<0.001 compared to untreated control, unpaired two-sided t-test.  
C,D: HepG2 cells were treated with (C) 1 μM Doxorubicin or (D) 50 μM Etoposide for the indicated time points. RT-
qPCR results for NOP14-AS1 and NOP14 normalized to Cyclophilin A and untreated control. Error bars represent SD 
(n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to untreated control, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
Since NOP14-AS1 was induced upon DNA damage in a p53-dependent manner, it was analyzed whether the 
DNA damage induced NOP14 repression was also p53-dependent. A p53 loss-of-function model in NCI-H460 
was generated using the earlier described dCas9-KRAB method. sgRNA#2, which was the most efficient sgRNA 
at repressing TP53 expression was used to generate a stable knockdown cell line in NCI-H460. TP53 silencing 
resulted in a loss of NOP14-AS1 induction as well as a partial rescue of NOP14 mRNA and protein expression 
upon Doxorubicin treatment (Figure 22A-D). The p53 target gene CDKN1A served as a positive control (Figure 
22E). Similar results were obtained in A549 cells (Figure 22F,G). As an alternative strategy to knockdown TP53, 
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NCI-H460 cells were transfected with an siPOOL against TP53. TP53 knockdown using an siPOOL again resulted 
in the loss of NOP14-AS1 induction as well as NOP14 repression upon Doxorubicin treatment (Figure 22H,I). 
 
Figure 22: NOP14-AS1 induction and NOP14 repression upon DNA damage are p53-dependent 
A-E: NCI-H460 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either a control sgRNA or a 
sgRNA targeting TP53. These were treated with either 1 μM Doxorubicin (DOXO) or vehicle control DMSO for 24 
hours. (A) RT-qPCR results for NOP14-AS1 and (B) NOP14 normalized to Cyclophilin A and control sgRNA + DMSO 
control. Error bars represent SD (n=5). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-
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sided t-test. (C) Western blot results for p53 and NOP14. GAPDH was used as a loading control. (D) Quantification of 
the NOP14 protein expression normalized to GAPDH and control sgRNA + DMSO control. (E) RT-qPCR results for 
CDKN1A normalized to Cyclophilin A and control sgRNA + DMSO control. Error bars represent SD (n=5). * p<0.05; ** 
p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test. 
F-G: A549 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either a control sgRNA or a sgRNA 
targeting TP53. These were treated with either 1 μM Doxorubicin (DOXO) or vehicle control DMSO for 24 hours. RT-
qPCR results for (F) NOP14-AS1, (H) NOP14 normalized to Cyclophilin A and control sgRNA + DMSO control. Error bars 
represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test. 
H,I: NCI-H460 cells were transfected with either siPOOL TP53 or siPOOL control. These were treated with either 1 μM 
Doxorubicin (DOXO) or vehicle control DMSO for 24 hours. RT-qPCR results for (E) NOP14-AS1 and (F) NOP14 
normalized to Cyclophilin A and siPOOL Control + DMSO control. Error bars represent SD (n=3). * p<0.05; ** p<0.01; 
*** p<0.001 compared to siPOOL Control, unpaired two-sided t-test.  
Data also used for a manuscript under review for publication: Goyal et al. 
 
Given the strong negative correlation between NOP14-AS1 and NOP14 expression in three different cell lines 
upon treatment with up to three different DNA damaging drugs, their co-dependence on p53 activation and 
their sense-antisense orientation, it was hypothesized that the NOP14-AS1 lncRNA transcript or its 
transcription would regulate NOP14 mRNA expression or vice versa as it had been proposed for several other 
examples of sense-antisense pairs 21, 22, 24, 32, 34, 138-144. 
A loss-of-function and a gain-of-function model would be required to experimentally validate this hypothesis. 
To address any transcript-dependent effects, a standard siRNA or antisense oligonucleotide mediated 
knockdown of NOP14-AS1 could serve as a loss-of-function model. On the hand a CRISPRi-based NOP14-AS1 
knockdown would have the additional advantage to shut down its transcription, thereby uncovering any 
transcription-dependent effects. Since the NOP14-AS1 locus gives rise to several splice isoforms, 
overexpression of all the variants using plasmid-based approach would be inefficient. On the other hand, a 
CRISPRa-mediated activation of NOP14-AS1 would induce all splice isoforms (at least from the targeted TSS). 
3.2.3. NOP14 does not regulate NOP14-AS1 upon DNA damage 
To analyze the impact of NOP14 repression on NOP14-AS1 expression, NOP14 was knocked down in NCI-H460 
cells using siRNAs. RNAi-induced loss of NOP14 mRNA and protein did not result in any NOP14-AS1 induction 
(Figure 23A-D). Treatment of these cells with Doxorubicin resulted in further repression of NOP14 but no 
further increase in NOP14-AS1 levels was observed (Figure 23A-D). This indicated that the increased NOP14-
AS1 expression upon doxorubicin treatment was not due to the reduced NOP14 expression. However, it was 
observed that the CDKN1A mRNA and protein expression was elevated upon NOP14 knockdown (Figure 
23B,E). Similar results were obtained in A549 cells (Figure 24), except that NOP14 knockdown using one of the 
two siRNAs resulted in decreased NOP14-AS1 induction upon Doxorubicin treatment (Figure 24D). However, 
since both siRNAs were equally effective in knocking down NOP14 expression (Figure 24A-C), this effect on 
NOP14-AS1 was most likely an off-target effect of this particular siRNA. 
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Figure 23: NOP14 knockdown using siRNAs does not affect NOP14-AS1 in NCI-H460 cells 
NCI-H460 cells were transfected with either a control siRNA (siControl) or two independent siRNAs (siNOP14(1) and 
siNOP14(2)) targeting the NOP14 mRNA. These were then treated with either 1 μM Doxorubicin (DOXO) or vehicle 
control DMSO for 24 hours. (A) RT-qPCR results for NOP14 normalized to Cyclophilin A and siControl + DMSO control. 
Error bars represent SD (n=5). * p<0.05; ** p<0.01; *** p<0.001 compared to control siRNA, unpaired two-sided t-
test. (B) Western blot results for PARP, NOP14, p53 and p21. GAPDH was used as a loading control. (C) Quantification 
of the NOP14 protein expression normalized to GAPDH and siControl + DMSO control. Error bars represent SD (n=3). 
* p<0.05; ** p<0.01; *** p<0.001 compared to control siRNA, unpaired two-sided t-test. RT-qPCR results for (D) 
NOP14-AS1 and (E) CDKN1A normalized to Cyclophilin A and siControl + DMSO control. Error bars represent SD (n=5). 
* p<0.05; ** p<0.01; *** p<0.001 compared to control siRNA, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
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Figure 24: NOP14 knockdown using siRNAs does not affect NOP14-AS1 in A549 cells 
A549 cells were transfected with either a control siRNA (siControl) or two independent siRNAs (siNOP14(1) and 
siNOP14(2)) targeting the NOP14 mRNA. These were treated with either 1 μM Doxorubicin (DOXO) or vehicle control 
DMSO for 24 hours. (A) RT-qPCR results for NOP14 normalized to Cyclophilin A and siControl + DMSO control. Error 
bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control siRNA, unpaired two-sided t-test. (B) 
Western blot results for PARP, NOP14, p53 and p21. GAPDH was used as a loading control. (C) Quantification of the 
NOP14 protein expression normalized to GAPDH and siControl + DMSO control. Error bars represent SD (n=3). * 
p<0.05; ** p<0.01; *** p<0.001 compared to control siRNA, unpaired two-sided t-test. RT-qPCR results for (D) NOP14-
AS1 and (E) CDKN1A normalized to Cyclophilin A and siControl + DMSO control. Error bars represent SD (n=3). * 
p<0.05; ** p<0.01; *** p<0.001 compared to control siRNA, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
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Since the RNAi-mediated knockdown of NOP14 could only rule out the possibility of any in trans-regulatory 
effects of NOP14 on NOP14-AS1, dCas9-KRAB was used to suppress the transcription of NOP14 from its 
endogenous promoter to uncover any in cis-regulatory effects. Indeed a dCas9-KRAB-mediated repression of 
NOP14 using two independent sgRNAs targeting its promoter resulted in a small but statistically significant 
induction (4-fold) of NOP14-AS1 steady-state expression (Figure 25A-D).  
 
Figure 25: NOP14 does not regulate NOP14-AS1 upon DNA damage 
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NCI-H460 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either a control sgRNA or one of the 
two indicated sgRNAs targeting NOP14. These were then treated with either 1 μM Doxorubicin (DOXO) or vehicle 
control DMSO for 24 hours. (A) RT-qPCR results for NOP14 normalized to Cyclophilin A and control sgRNA + DMSO 
control. Error bars represent SD (n=4). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-
sided t-test. (B) Western blot results for PARP, NOP14, and p53. GAPDH was used as a loading control. (C) 
Quantification of the NOP14 protein expression normalized to GAPDH and control sgRNA + DMSO control. Error bars 
represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test. RT-qPCR 
results for (D) NOP14-AS1 and (E) CDKN1A normalized to Cyclophilin A and control sgRNA + DMSO control. Error bars 
represent SD (n=4). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
 
However, this induction was much weaker than the Doxorubicin-mediated increase of NOP14-AS1 (22-fold) in 
these cells (Figure 25D). Also, the decrease of NOP14 by CRISPRi and DNA damage led to comparable NOP14 
levels, but to vastly different NOP14-AS1 levels (Figure 25A-D). Moreover, no significant further increase in 
NOP14-AS1 levels upon NOP14 knockdown was observed in the Doxorubicin-treated cells (Figure 25D), 
altogether indicating that an independent mechanism was responsible for NOP14-AS1 induction upon DNA 
damage. 
Interestingly, p53 levels were slightly elevated in the NOP14 knockdown cells (Figure 25B, Exp#1) but upon 
Doxorubicin treatment in these cells, p53 expression was consistently less than what was observed in the 
control cells (Figure 25B) indicating a role in the p53 pathway. PARP cleavage, which served as an indicator for 
apoptosis induction was also reduced upon NOP14 knockdown in Doxorubicin-treated cells (Figure 25B). But 
since the uncleaved PARP levels were also affected in the DMSO-treated cells, no conclusions could be drawn 
about the effect of NOP14 on Doxorubicin-induced apoptosis.  
In line with the results from the siRNA-mediated knockdown of NOP14, CDKN1A was also induced upon dCas9-
KRAB-mediated NOP14 knockdown (Figure 25E) which could be explained by the mild increase in p53 levels in 
NOP14 knockdown cells (Figure 25B, Exp#1). Simultaneous knockdown of TP53 in the NOP14 CRISPRi 
knockdown cells resulted in a complete loss of CDKN1A induction, indicating that the CDKN1A induction 
observed upon dCas9-KRAB-mediated NOP14 knockdown was indeed due to p53 stabilization (Supplementary 
Figure 34B). TP53 knockdown, however, could not prevent the NOP14-AS1 induction observed upon dCas9-
KRAB-mediated NOP14 knockdown, indicating that this was a p53-independent event (Supplementary Figure 
34C).  
It was also observed that NOP14 knockdown resulted in severe proliferation defects and the stable NOP14 
knockdown cell lines stopped proliferating beyond second passage in cell culture (Figure 26) indicating a role 
of NOP14 in cell proliferation. The reduced proliferation upon NOP14 knockdown could be due to cell cycle 
arrest induced by increased CDKN1A expression in these cells. 
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Figure 26: NOP14 knockdown results in growth arrest 
NCI-H460 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either a control sgRNA or one of the 
two indicated sgRNAs targeting NOP14. Equal numbers of cells for the each stable cell line were seeded. Brightfield 
images from three independent experiments 6 days post seeding. 
 
To test whether the small induction of NOP14-AS1 upon dCas9-KRAB-mediated NOP14 knockdown was a 
specific and rescuable effect, NOP14 was exogenously expressed from a lentiviral plasmid in the NOP14 
knockdown cells. NOP14 cDNA from NCI-H460 cells was cloned into a lentiviral plasmid downstream of a 
constitutive promoter (EF1α) and transduced into NOP14 knockdown cells. Since the sgRNA binding site was 
absent in the lentiviral plasmid containing the NOP14 cDNA, it could rescue NOP14 expression in these cells 
even though the transcription from the endogenous NOP14 promoter continued to be repressed (Figure 27A-
C). 
Ectopic expression of NOP14 expression resulted in only a partial reversal of the NOP14-AS1 induction 
observed upon NOP14 knockdown using dCas9-KRAB (Figure 27D). The CDKN1A induction observed upon 
NOP14 knockdown could also be reversed completely (Figure 27E) indicating that CDKN1A was induced as a 
result of reduced NOP14 mRNA or protein levels rather than its transcription. Similarly, the induction of p53 
observed upon NOP14 knockdown could also be reversed (Figure 27B). The reduced PARP levels were also 
restored further confirming a role of NOP14 in regulating PARP levels inside these cells (Figure 27B). Taken 
together these data indicate that the small increase in NOP14-AS1 expression observed with the CRISPRi 
approach was a result of in cis-regulation by transcriptional interference, but that the DNA damage-induced 
regulation of NOP14-AS1 was independent of NOP14 expression.  
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Figure 27: Ectopic rescue of NOP14 expression does not reverse NOP14-AS1 induction 
A-D: NCI-H460 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either a control sgRNA or a 
sgRNA targeting NOP14 in combination with either lenti EGFP Blast or lenti NOP14 Blast. These were treated with 
either 1 μM Doxorubicin (DOXO) or vehicle control DMSO for 24 hours. (A) RT-qPCR results for NOP14 normalized to 
Cyclophilin A and control sgRNA + DMSO control. Error bars represent SD (n=6). * p<0.05; ** p<0.01; *** p<0.001 
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compared to control sgRNA, unpaired two-sided t-test. (B) Western blot results for PARP, NOP14, and p53. GAPDH 
was used as a loading control. (C) Quantification of the NOP14 protein expression normalized to GAPDH and control 
sgRNA + DMSO control. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, 
unpaired two-sided t-test. RT-qPCR results for (D) NOP14-AS1 and (E) CDKN1A normalized to Cyclophilin A and control 
sgRNA + DMSO control. Error bars represent SD (n=6). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, 
unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
In turn, NOP14-AS1 could regulate NOP14 expression upon DNA damage thereby exerting its function in the 
DDR. 
3.2.4. NOP14-AS1 does not regulate NOP14 upon DNA damage 
To analyze the impact of the NOP14-AS1 transcript on NOP14 expression, NOP14-AS1 was knocked down in 
NCI-H460 cells using two independent antisense LNA GapmeRs. The cells were treated with Doxorubicin or 
vehicle control (DMSO). Despite the reduced NOP14-AS1 expression, no significant increase in NOP14 mRNA or 
protein expression could be observed. Moreover, NOP14-AS1 knockdown could not rescue the Doxorubicin-
induced NOP14 repression (Figure 28A-D) indicating that increased NOP14-AS1 lncRNA transcript levels was 
not responsible for the NOP14 regulation upon Doxorubicin treatment. Also, no changes in the PARP (cleaved 
or uncleaved) and p53 levels, as well as the CDKN1A expression, were observed upon NOP14-AS1 knockdown 
(Figure 28C,E). 
To establish whether NOP14-AS1 can regulate NOP14 expression in cis via transcription-dependent 
mechanisms, NOP14-AS1 transcription was modulated by using the earlier established method of CRISPRi 
using dCas9-KRAB. From the initial panel of five sgRNAs used to repress NOP14-AS1 (Figure 7A), sgRNA#1 and 
sgRNA#3 were chosen for dCas9-KRAB-mediated knockdown of NOP14-AS1. Additionally to the dCas9-KRAB-
mediated loss-of-function model, a dCas9-VP160 mediated CRISPRa gain-of-function model was also 
established. To identify sgRNAs that can efficiently activate NOP14-AS1 transcription, an initial screening using 
a panel of eight sgRNAs was performed. All sgRNAs (including sgRNA#3) that bound a region downstream of 
the NOP14-AS1 TSS, failed to activate its transcription. The upstream sgRNA#1 and sgRNA#6 were the most 
efficient in activating NOP14-AS1 transcription and were therefore used for the subsequent experiments 
(Supplementary Figure 35). 
Repression or induction of NOP14-AS1 transcription from its endogenous promoter using two independent 
sgRNAs was effective in NOP14-AS1 regulation (Figure 29A), but did not result in any change in NOP14 mRNA 
or protein expression. Moreover, NOP14-AS1 transcriptional modulation using CRISPRi/CRISPRa had no impact 
on Doxorobucin induced NOP14 repression (Figure 29B-D), indicating that the NOP14 repression upon DNA 
damage was independent of NOP14-AS1 lncRNA transcript as well as transcription. Also, no changes were 
observed in the PARP (cleaved or uncleaved), p53 and CDKN1A mRNA as well as protein expression upon 
NOP14-AS1 knockdown. Similar results were obtained in A549 cells (Figure 30) further confirming that NOP14-
AS1 had no impact on NOP14 mRNA or protein expression. 
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Figure 28: NOP14-AS1 knockdown using LNA antisense GapmeRs  
A-D: NCI-H460 cells were transfected with either a control GapmeR or one of the two indicated GapmeRs (GapmeR#1 
and GapmeR#2) targeting the NOP14-AS1 lncRNA. These were treated with either 1 μM Doxorubicin (DOXO) or 
vehicle control DMSO for 24 hours. (A) RT-qPCR results for NOP14 normalized to Cyclophilin A and control GapmeR + 
DMSO control. Error bars represent SD (n≥3). * p<0.05; ** p<0.01; *** p<0.001 compared to control GapmeR, 
unpaired two-sided t-test. (B) Western blot results for PARP, NOP14, and p53. GAPDH was used as a loading control. 
(C) Quantification of the NOP14 protein expression normalized to GAPDH and control GapmeR + DMSO control. Error 
bars represent SD (n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control GapmeR, unpaired two-sided t-test. 
RT-qPCR results for (D) NOP14-AS1 and (E) CDKN1A normalized to Cyclophilin A and control GapmeR + DMSO control. 
Error bars represent SD (n≥3; except for CDKN1A, for which n≥2). * p<0.05; ** p<0.01; *** p<0.001 compared to 
control GapmeR, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
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Figure 29: NOP14-AS1 transcription modulation in NCI-H460 cells has no impact on NOP14 expression 
NCI-H460 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA or lentidCas9-VP160-PURO iv sgRNA, 
respectively, containing either a control sgRNA or one of the two indicated sgRNAs targeting the NOP14-AS1 
promoter. These were then treated with either 1 μM Doxorubicin (DOXO) or vehicle control DMSO for 24 hours. (A) 
RT-qPCR results for NOP14 normalized to Cyclophilin A and control sgRNA + DMSO controls. Error bars represent SD 
(n=3). * p<0.05; ** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test. (B) Western blot 
results for PARP, NOP14, and p53 and p21. GAPDH was used as a loading control. (C) Quantification of the NOP14 
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protein expression normalized to GAPDH and control sgRNA + DMSO control. Error bars represent SD (n=3). * p<0.05; 
** p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
 
 
Figure 30: NOP14-AS1 transcription modulation in A549 cells has no impact on NOP14 expression 
A549 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA or lentidCas9-VP160-PURO iv sgRNA, respectively, 
containing either a control sgRNA or one of the two indicated sgRNAs targeting the NOP14-AS1 promoter. These were 
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then treated with either 1 μM Doxorubicin (DOXO) or vehicle control DMSO for 24 hours. (A) RT-qPCR results for 
NOP14 normalized to Cyclophilin A and control sgRNA + DMSO controls. Error bars represent SD (n=3). * p<0.05; ** 
p<0.01; *** p<0.001 compared to control sgRNA, unpaired two-sided t-test. (B) Western blot results for PARP, 
NOP14, and p53 and p21. GAPDH was used as a loading control. (C) Quantification of the NOP14 protein expression 
normalized to GAPDH and control sgRNA + DMSO control. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** 
p<0.001 compared to control sgRNA, unpaired two-sided t-test. 
Data also used for a manuscript under review for publication: Goyal et al. 
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4. Discussion 
4.1. CRISPRi for lncRNA knockdown: Lessons from the NOP14-AS1 locus 
Besides achieving a successful knockdown, NOP14-AS1 targeting using dCas9/dCas9-KRAB (Figure 7) revealed 
two things about the CRISPRi system: (1) dCas9-KRAB was more efficient as compared to dCas9 and (2) 
dCas9/dCas9-KRAB mediated knockdown of a lncRNA can affect transcription of a neighboring gene. It was not 
surprising that dCas9-KRAB was a more potent inhibitor of NOP14-AS1, as this phenomenon was already 
observed by others while using this system for knockdown of protein-coding genes96. dCas9 is suggested to 
inhibit transcription initiation or elongation by sterically hindering the RNA polymerase95. Fusing an additional 
transcriptional repressor domain of KRAB to dCas9 was expected to make it more effective at transcriptional 
inhibition. Nevertheless, the simultaneous knockdown of MFSD10, while targeting NOP14-AS1 was 
unexpected. Two possible explanations could be invoked: either this was an artifact of CRISPRi or a 
consequence of an in cis-regulatory relationship between NOP14-AS1 and MFSD10. An ASO-mediated 
knockdown of NOP14-AS1, did not affect the MFSD10 expression ruling out any transcript-dependent in cis 
effect of NOP14-AS1 on MFSD10 expression. However, it was still possible that the reduced NOP14-AS1 
transcription could lead to reduced MFSD10 expression. 
To further demonstrate that this phenomenon was indeed an artifact of the technique and not a locus-specific 
effect, this system was tested for five additional loci: TP53/WRAP53, HOXD1/HOXD-AS1, RB1/LINC00441, 
MNX1/MNX1-AS1 and HOXC11/HOTAIR (Figure 8, Figure 9, Figure 10, Figure 11, Figure 12, Figure 13). In all 
these cases, a dCas9-KRAB mediated knockdown of the intended target resulted in simultaneous knockdown 
of the neighboring gene, while RNAi- or ASO-based approaches did not show such effects. Furthermore, the 
results from HOTAIR knockdown suggested that dCas9-KRAB could only target expression from the promoters 
which are in proximity to that of the intended target (Figure 13). A recent study on the genome-scale 
repression of protein-coding genes using CRISPRi concluded that dCas9-KRAB repressed promoters when 
recruited within a span of up to 2 kb. These results are in agreement with the observations from 
HOXC11/HOTAIR locus. 
Given that lncRNA loci are often found overlapping or in close proximity to other genes, it is possible that the 
use of CRISPRi to specifically knockdown a lncRNA is not possible for a vast proportion of lncRNAs. Such 
lncRNAs could be called “non-CRISPRable”. For example, all lncRNAs arising from bidirectional promoters are 
non-CRISPRable (Figure 31A). Similarly, all lncRNAs whose promoters lie in a close proximity to the promoters 
of other genes are also non-CRISPRable (Figure 31B). Since dCas9/dCas9-KRAB can also affect transcription 
elongation by sterically blocking the movement of RNA Polymerase, internal lncRNAs are also non-CRISPRable 
(Figure 31C). Only those lncRNAs, which do not fall in any of the above-mentioned categories, could be 
targeted by CRISPR-based approaches without directly targeting other genes in the same locus (Figure 31D).  
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Figure 31:  lncRNA CRISPRability based on its genomic context 
Schematic representation of dCas9-KRAB-mediated knockdown of a lncRNA arising from (A) a bi-directional promoter, 
(B) a promoter proximal to the promoter of another gene, (C) an internal promoter or (D) an independent promoter 
with no proximal promoter. 
 
Similarly, a Cas9-mediated excision of full-length lncRNA loci, though straightforward for intergenic lncRNAs, is 
impossible for intragenic lncRNAs overlapping with another gene as this will also lead to deletion of the 
sequences of those genes. Also, deletion of lncRNA promoters can only be performed for those lncRNAs which 
arise from external and independent promoters. For lncRNAs arising from internal/bidirectional promoters, 
such a deletion could also affect their overlapping/neighboring genes. In some cases, it might be possible to 
generate a functional knockout by deleting a part of the lncRNA which is distant from its promoter and not 
overlapping with any other gene145. However, for many lncRNAs, their functional domain lies in the promoter 
proximal or the part overlapping with other gene34, 43. In such cases, deletion of the promoter distal elements 
would have no effect on the lncRNA function. Also, deleting a part of the lncRNA without removing its 
transcriptional start site (TSS) could potentially lead to the generation of a new gene body with potentially new 
functions.  
A genome-wide bioinformatic analysis to determine the fraction of CRISPRable lncRNAs was performed in the 
lab by Ksenia Myacheva. She found that only 38% of the total annotated lncRNAs were CRISPRable whereas 
62% lncRNAs were not safely amenable to CRISPR/Cas9-mediated approaches (20% due to the bidirectional 
promoter, 7% due to proximal promoters, and 35% due to the internal promoter)116. A recent study utilizing 
dCas9-KRAB to identify lncRNA genes essential for cell proliferation found a total of 439 hits. However, out of 
these 439 lncRNAs, 169 were located within a 1 kb distance from the promoter a protein-coding which was 
also essential for cell proliferation in a different CRISPRi screen for essential protein-coding genes104, 106. This 
further validates the argument that CRISPRi should be used carefully for lncRNAs. In summary, the CRISPRi 
system provides an important and essential tool that also comparatively easily allows genome-wide screens. 
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However, the limitations of this system need to be taken into account in order to obtain relevant and 
biologically significant results for the genes targeted. The complexity of the targeted gene locus needs to be 
evaluated for sgRNA design and data analysis. Also, to avoid false positives, validation using orthogonal 
techniques like RNAi-based methods using siRNAs, siPOOLs or shRNAs or RNase H-mediated RNA degradation 
using ASOs or GapmeRs should complement the CRISPR-based experiments.  
4.2. NOP14-AS1: A DNA damage induced lncRNA 
LncRNAs play an important role in diverse cellular processes and the DDR is one of them. With an aim to 
identify novel lncRNAs involved in DDR, the Diederichs lab performed a microarray expression analysis of 
lncRNAs in cells treated with DNA damaging agents. This analysis identified lncRNA NOP14-AS1 to be induced 
upon DNA damage. One of the aims of this Ph.D. project was to further characterize the regulation of NOP14-
AS1 in DNA damage.  
In order to characterize the NOP14-AS1 regulation in DNA damage, it was important to characterize its full-
length sequence first. RACE analysis performed on cDNA from HepG2 cells identified that this gene gave rise to 
several splice isoforms arising from a total of three distinct TSSs (Figure 15). Multiple splice isoforms and a 
degenerate 5’ end are a common feature of lncRNAs arising from such complex loci146, 147. Analysis of the 
publically available RNA-seq data for several cell lines corroborated the observations from RACE analysis 
(Figure 15). Analysis of the Encode CAGE data revealed that the first TSS accounted for most of the expression 
from the NOP14-AS1 locus even though the number of clones obtained from 5’RACE was equally distributed 
for all the three TSSs (Figure 15). One possible explanation for this observation could be that since this analysis 
was performed on cDNA obtained from HepG2 cells treated with Etoposide, it could be that the second and 
third TSSs are transcriptionally more active upon DNA damage induction while the first TSS is constitutively 
active. Another possibility is that RACE analysis is not quantitative and is often biased towards detection of 
shorter isoforms. Nevertheless, this data proved to be of immense use in designing not only the RT-qPCR 
amplicons used to detect NOP14-AS1 expression but also the LNA antisense GapmeRs as well as the sgRNAs 
used to knockdown/overexpress NOP14-AS1 later during the course of this dissertation project. This analysis 
also advocates for exploitation of publically available RNA-seq and CAGE data for lncRNA research in 
combination with RACE and RT-qPCR experiments. 
Treatments in four cell lines using a panel of five DNA damaging drugs established that the NOP14-AS1 
induction was not a cell type- or drug-specific effect (Figure 16). NCI-H460 cells showed the highest induction 
of NOP14-AS1 and were therefore used as the preferred cell line model for the rest of the study. DNA damage-
dependent NOP14-AS1 induction was a transcriptional response (Figure 17) as was the case for most of the 
DNA damage induced lncRNAs. NOP14-AS1 was induced in A549, NCI-H460 as well as HepG2 cells upon 
treatment with Nutlin-3 (Figure 18A). Also, Etoposide and Doxorubicin treatment in wt HCT-116 cells resulted 
in NOP14-AS1 induction, while TP53-deficient HCT-116 cells showed no such induction (Figure 18C). Moreover, 
TP53 knockdown using dCas9-KRAB or an siPOOL in NCI-H460 and A549 cells also resulted in a loss of NOP14-
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AS1 induction upon Doxorubicin treatment (Figure 22). These results indicated that p53 was necessary and 
sufficient for NOP14-AS1 upon DNA damage and add NOP14-AS1 to the growing list of lncRNAs that are p53 
regulated, such as lincRNA-p21, PANDAR, DINO etc.51. However, it is still not determined whether NOP14-AS1 
is a direct target of p53 as no canonical p53-binding sites could be detected in the NOP14-AS1 promoter using 
the p53scan tool148. A p53 chip-seq could be performed to determine whether p53 binds to the NOP14-AS1 
promoter. The p53 response element thus determined could then be mutated (using Cas9 for example) and 
this could also serve as a loss-of-function model for NOP14-AS1 in DNA damage. Most of the lncRNAs induced 
by p53 were also shown to play a role in modulating the p53 pathway51. This could argue for a role of NOP14-
AS1 in the p53 pathway. 
4.3. NOP14-AS1 and NOP14 inverse co-regulation 
Time course expression analysis in NCI-H460, A549, and HepG2 cells treated with one of the three DNA 
damaging drugs (Doxorubicin, Etoposide, and Cisplatin) revealed a striking inverse co-regulation of NOP14 
(mRNA as well as protein) and NOP14-AS1 (Figure 19, Figure 20, Figure 21). Moreover, the observed NOP14-
AS1 and NOP14 regulation were p53-dependent (Figure 22). Such DNA damage induced inverse co-regulation 
of a sense-antisense pair was previously observed for INK4b and the lncRNA ANRIL42. While INK4b expression 
was reduced, ANRIL expression was elevated upon DNA damage (caused by Etoposide, Bleomycin, and 
Neocarzinostatin). The same study concluded that ANRIL was induced via the ATM-E2F pathway and was 
responsible for INK4b repression observed upon DNA damage, establishing that a stimulus-induced inverse co-
regulation of a sense-antisense pair of mRNA and lncRNA could indicate a functional interplay between them. 
Another example of a sense-antisense pair which shows a stimulus-dependent co-regulation is that of the IL-
1α mRNA and its antisense lncRNA AS-IL1α. AS-IL1α is induced in bone marrow-derived macrophages upon 
Lipopolysaccharide (LPS) stimulation. Concurrent to the AS-IL1α induction, IL-1α transcription is also enhanced 
in an AS-IL1α-dependent manner149. 
Antisense lncRNAs often regulate the expression of their overlapping sense protein-coding genes through 
diverse mechanisms. At the level of transcription, they can induce promoter DNA methylation22, 24, 141, recruit 
histone modifying enzymes21, 44, 142, 144, 150-152, directly interfere and block the transcriptional machinery via 
transcriptional interference28, 140, 153, 154, or regulate sense mRNA splicing143, 155, 156. Post-transcriptionally, they 
can bind to their sense mRNA and increase its stability by masking miRNA-binding sites32 or enhance its 
translation by recruiting additional factors34. Although they can also act in trans to regulate the expression of 
other genes, antisense lncRNAs are suggested to act more frequently in cis due to their proximity to their 
overlapping sense genes19, 157. The inverse co-regulation of the sense-antisense pair of NOP14 and NOP14-AS1 
and their co-dependence on p53 was a strong indicator of a possible functional relationship between them and 
therefore demanded further interrogation. 
61 
 
4.4. NOP14 and its role in NOP14-AS1 regulation 
NOP14 knockdown in NCI-H460 as well as A549 cells using siRNAs, had no effect on NOP14-AS1 expression 
(Figure 23, Figure 24). One possible explanation could be that either NOP14 does not affect NOP14-AS1 
expression or NOP14 mRNA regulates the NOP14-AS1 expression in cis similar to several other mRNAs158, and 
such a regulatory relationship could not be uncovered by the RNAi-mediated knockdown. In line with this 
argument, a dCas9-KRAB-mediated repression of NOP14 transcription resulted in a moderate NOP14-AS1 
induction (Figure 25). This induction (4-fold) was however not comparable to the much stronger induction (22-
fold) observed upon Doxorubicin treatment, despite similar expression levels of NOP14 (Figure 25). Moreover, 
there was no further increase in NOP14-AS1 induction in the NOP14 knockdown cells upon Doxorubicin 
treatment, despite the increased NOP14 repression. These data indicate that the NOP14-AS1 induction upon 
Doxorubicin treatment was due to an independent mechanism. NOP14-AS1 induction observed upon NOP14 
knockdown using dCas9-KRAB was likely due to reduced transcriptional interference resulting from a reduction 
in NOP14 transcription. In line with this argument, a plasmid-based rescue of NOP14 expression in the NOP14 
knockdown cells did not result in a loss of NOP14-AS1 induction (Figure 27). These results are of particular 
significance, as they demonstrate that CRISPRi can be used to study transcriptional interference between 
overlapping genes. 
Interestingly, NOP14 knockdown using siRNAs, as well as dCas9-KRAB, resulted in the induction of CDKN1A 
(Figure 23, Figure 24, Figure 25). This could be explained by the p53 stabilization upon NOP14 knockdown, 
which could also be reversed upon ectopic rescue of NOP14 expression (Figure 25, Figure 27). NOP14 is a 
nucleolar protein where it is involved in the biogenesis of the small ribosomal subunit159, 160. It is a part of 
complex which is required for nucleolar localization of the EMG1, an RNA methyltransferase that is required 
for 18S rRNA processing160-162. The detected downregulation of NOP14 could correspond to the nucleolar 
stress-mediated p53 stabilization163 or DNA damage-induced inhibition of rRNA synthesis164, 165.  
4.5. NOP14-AS1 and its role in NOP14 regulation 
An LNA antisense GapmeR-based knockdown of NOP14-AS1 did not produce any significant impact on NOP14 
expression in the presence or absence of Doxorubicin (Figure 28) indicating that NOP14 repression upon DNA 
damage was not NOP14-AS1 lncRNA transcript driven. In the previous studies on ANRIL and AS-IL1α, an RNAi-
based knockdown was sufficient to reverse the effect of these lncRNAs on their respective overlapping 
protein-coding genes42, 149. An RNAi-based knockdown of NOP14-AS1 was also attempted using several siRNAs 
and also an siPOOL, but these reagents did not give a satisfactory knockdown. However, the ASO-based 
knockdown resulted in decreased NOP14-AS1 levels and this should ideally be sufficient to at least partially 
reverse the repression of NOP14 if mediated by the NOP14-AS1 transcript. Again, two possible explanations 
for this observation could be invoked: either NOP14 expression was independent of NOP14-AS1 or the DNA 
damage-induced NOP14-AS1 transcription and not the transcript itself was responsible for NOP14 repression. 
To dissect these possibilities, a CRISPRi-mediated transcription repression and a CRISPRa-mediated 
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transcriptional activation of NOP14-AS1 also did not have any impact on NOP14 expression (Figure 29, Figure 
30) making it clear that NOP14-AS1 had no role in the regulation of NOP14 in DNA damage. Moreover, unlike 
NOP14 knockdown, NOP14-AS1 knockdown cells did not show any obvious growth defects. Also, no effects on 
p53, PARP or CDKN1A expression were observed. 
The CRISPRi-based loss-of-function model should be able to uncover any possible regulatory relationship 
between NOP14-AS1 and NOP14. However, to rule out that any low-level expression from the NOP14-AS1 
could still impact NOP14 expression, Berta Duran Arqué generated a NOP14-AS1 deletion clone in Hek293 cells 
using Cas9. Hek293 cells were co-transfected with Cas9 and two sgRNAs spanning the non-overlapping part of 
the NOP14-AS1 gene (Figure 32A). The clonal selection followed by genotyping identified one homozygous 
(clone #51) and four heterozygous deletion clones (Figure 32A).  
 
Figure 32: NOP14-AS1 deletion in Hek293 using CRISPR/Cas9 
A: Upper panel: Schematic representation of the NOP14-AS1 genomic locus depicting the sgRNAs used to delete 
NOP14-AS1 as well as the RT-qPCR amplicons used to detect NOP14-AS1 expression. Lower panel: Hek293 cells were 
transfected with PX458-2X sgRNA plasmid, which expressed Cas9 as well as the two indicated sgRNAs. 48 hours post-
transfection, cells were single cell sorted and allowed to grow for 2 weeks. The clones thus obtained were screened 
for NOP14-AS1 deletion. Sanger sequencing results of the five homozygous deletion clones obtained. 
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B,C: RT-qPCR results for (B) NOP14-AS1 as measured using two different amplicons and (C) MFSD10 and NOP14 
normalized to Cyclophilin A and Hek293 wild type (wt) cells. Error bars represent SD (n=3). * p<0.05; ** p<0.01; *** 
p<0.001 compared to wt cells, unpaired two-sided t-test. 
Data used here has been generated by Berta Duran Arque under the supervision of Ashish Goyal and published as a 
part of the following manuscript: Goyal et al., Nucleic Acids Res, 2016116. 
 
Expression analysis revealed that NOP14-AS1 expression was significantly reduced in all deletion clones. Clone 
#51 had no detectable NOP14-AS1 expression as measured using RT-qPCR Amplicon#1. However, there was 
some residual NOP14-AS1 expression as measured using Amplicon#2 (Figure 32B). This could be because 
Amplicon#2 lies outside the deleted region. Despite significant knockdown of NOP14-AS1 in all five clones, 
NOP14 expression was not significantly changed (Figure 32B,C). MFSD10 expression was affected in these 
clones possibly due to deletion of promoter elements (Figure 32C) again advocating for caution while using 
Cas9 to knockout lncRNA genes.  
Taken together, these experiments did not detect any role of NOP14-AS1 in the regulation of NOP14. It is quite 
possible that NOP14-AS1 plays a role in DNA damage response further downstream which is yet to be 
discovered. Given that its regulation upon DNA damage is controlled by p53, it could play a role in the p53 
pathway as lincRNA-p21, PANDAR, DINO, lincRNA-ROR or PINT. However, no changes in p53, as well as 
CDKN1A expression, were observed upon NOP14-AS1 knockdown or overexpression. This might indicate a 
further downstream role of this lncRNA similar to lincRNA-p21 or PANDAR, which do not regulate the p53 
levels but instead regulate the expression of selected p53 target genes. Since the loss-of-function and gain-of-
function models for NOP14-AS1 have been established, these could be used to perform gene expression 
analysis using microarray or RNA-seq to identify genes that are affected by NOP14-AS1 regulation. The gene 
sets identified could be scanned for any overlaps with p53 target genes. There is also a possibility to find 
protein interaction partners of NOP14-AS1 using techniques like RAP-MS (RNA antisense purification- mass 
spectrometry)166 or ChiRP-MS (comprehensive identification of RNA-binding proteins by mass spectrometry)167, 
168. 
4.6. Conclusions 
Previously, NOP14-AS1 was identified as a DNA damage-regulated lncRNA and that it may be inversely co-
regulated with its neighboring protein-coding gene NOP14. In this study, I analyze the regulatory mechanisms 
of this induction and whether this sense-antisense pair of NOP14 and NOP14-AS1 shares a cis-regulatory 
relationship. I demonstrate that NOP14-AS1 is a p53-inducible lncRNA which undergoes transcriptional 
induction upon DNA damage. I confirm the significant inverse co-regulation of NOP14-AS1 and NOP14 in 
multiple cell lines using multiple DNA-damaging drugs and demonstrate that both co-dependent on p53 for 
regulation upon DNA damage. Using the state-of-the-art CRISPR/Cas9 system, I was able to demonstrate that 
neither NOP14 nor NOP14-AS1 regulate the expression of each other. In the process of establishing this 
system, I experimentally demonstrate a major limitation of the CRISPRi system for lncRNA knockdown: CRISPRi 
targeting of a lncRNA arising from a complex locus can unintentionally affect the expression of its neighboring 
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genes. These results demonstrate that not all lncRNA-mRNA sense-antisense pairs necessarily regulate each 
other even if their expression is correlated and affected by the same pathways, and call for caution when 
functional interpretations are drawn based on the correlation between sense-antisense pairs in genome-wide 
expression studies.  
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Appendix 
4.7. Supplementary Figures 
 
Figure 33: NOP14-AS1 transcriptional modulation using dCas9 
A: Schematic representation of the MFSD10 / NOP14-AS1 genomic locus depicting the sgRNAs used to target NOP14-
AS1. B: A549 cells expressing dCas9 were transduced with either Control sgRNA or one of the seven indicated sgRNAs 
targeting NOP14-AS1 promoter. RT-qPCR results for NOP14-AS1 normalized to Cyclophilin A and control sgRNA. Data 
obtained from a single experiment. Not followed up upon due to the superior knockdown results with KRAB. 
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Figure 34: CDKN1A induction upon NOP14 knockdown is p53-dependent 
NCI-H460 cells were transduced with lentidCas9-KRAB-PURO iv sgRNA containing either a control sgRNA or one of the 
two independent sgRNAs targeting NOP14. These were transfected with either a control siPOOL or an siPOOL 
targeting TP53 following which these treated with either 1 μM Doxorubicin (DOXO) or vehicle control DMSO for 24 
hours. RT-qPCR results for (A) NOP14, (B) CDKN1A and (C) NOP14-AS1 normalized to Cyclophilin A and control sgRNA 
+ siPOOL control + DMSO control. Data obtained from a single experiment. 
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Figure 35: NOP14-AS1 transcriptional activation using dCas9-VP160 
A: Schematic representation of the MFSD10 / NOP14-AS1 genomic locus depicting the sgRNAs used to target NOP14-
AS1. 
B: A549 cells expressing dCas9-VP160 were transduced with either Control sgRNA or one of the eight indicated 
sgRNAs targeting NOP14-AS1 promoter. RT-qPCR results for NOP14-AS1 normalized to Cyclophilin A and control 
sgRNA. Data obtained from a single experiment. Not followed up upon as the aim was to identify two most efficient 
sgRNAs.  
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4.8. Supplementary sequences 
Table 9: Common sequence features of the plasmids used in this study 
Name Sequence 
dCas9 
ATGGACAAGAAGTACAGCATCGGCCTGGCCATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCG
ACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATCAAGAA
GAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCCACCCGGCTGAAGAGAACC
GCCAGAAGAAGATACACCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGA
TGGCCAAGGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAA
GCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCACC
ATCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCGGCTGATCTATCTGG
CCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAG
CGACGTGGACAAGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATC
AACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAA
ATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGCAACCTGATTGCCCTGAGCCT
GGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAG
GACACCTACGACGACGACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTC
TGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCAC
CAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACCCTGCTG
AAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAACG
GCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCT
GGAAAAGATGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAG
CGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGGC
GGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAGATCCTGACCTTCCG
CATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGC
GAGGAAACCATCACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCA
TCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCT
GTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAG
CCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAG
TGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTC
CGGCGTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGAC
AAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACTGT
TTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACCTGTTCGACGACAAAGTGAT
GAAGCAGCTGAAGCGGCGGAGATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATC
CGGGACAAGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACT
TCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTGTCCGG
CCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCCGCCATTAAGAAGGGCATC
CTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCG
TGATCGAAATGGCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAA
GCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACC
CAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGATATGTACGTGGACCAGG
AACTGGACATCAACCGGCTGTCCGACTACGATGTGGACGCCATCGTGCCTCAGAGCTTTCTGAAGGA
CGACTCCATCGACAACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCC
TCCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTACCC
AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACTGGATAAGGCCGGCTT
CATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGG
ATGAACACTAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCA
AGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCA
CGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAA
AGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGAGCGAGCAGG
AAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGAT
TACCCTGGCCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATC
GTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGAATATCG
TGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCCTGCCCAAGAGGAACAGCGA
TAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTG
GCCTATTCTGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAG
AGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGAAGC
CAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTG
GAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGC
84 
 
Table 9: Common sequence features of the plasmids used in this study 
Name Sequence 
CCTCCAAATATGTGAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGA
TAATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATC
AGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCGCCTACAACA
AGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATCATCCACCTGTTTACCCTGACCAATCT
GGGAGCCCCTGCCGCCTTCAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAA
GAGGTGCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGT
CTCAGCTGGGAGGCGAC 
XTEN-
Linker 
AGCGGCAGCGAGACACCCGGCACAAGCGAGTCTGCCACCCCCGAGTCT 
KRAB 
AGAACACTGGTGACCTTCAAGGATGTATTTGTGGACTTCACCAGGGAGGAGTGGAAGCTGCTGGACA
CTGCTCAGCAGATCGTGTACAGAAATGTGATGCTGGAGAACTATAAGAACCTGGTTTCCTTGGGTTA
TCAGCTTACTAAGCCAGATGTGATCCTCCGGTTGGAGAAGGGAGAAGAGCCCTGGCTGGTG 
VP160 
GACGCGCTGGACGATTTCGATCTCGACATGCTGGGTTCTGATGCCCTCGATGACTTTGACCTGGATA
TGTTGGGAAGCGACGCATTGGATGACTTTGATCTGGACATGCTCGGCTCCGATGCTCTGGACGATTT
CGATCTCGATATGTTAGGGTCAGACGCACTGGATGATTTCGACCTTGATATGTTGGGAAGCGATGCC
CTTGATGATTTCGACCTGGACATGCTCGGCAGCGACGCCCTGGACGATTTCGATCTGGACATGCTGG
GGTCCGATGCCTTGGATGATTTTGACTTGGATATGCTGGGGAGTGATGCCCTGGACGACTTTGACCT
GGACATGCTGGGCTCCGATGCGCTCGATGACTTCGATTTGGATATGTTGGGATCC 
P2A GCAACAAACTTCTCTCTGCTGAAACAAGCCGGAGATGTCGAAGAGAATCCTGGACCG 
PUROR 
ACCGAGTACAAGCCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCCAGGGCCGTACGCACCCTCG
CCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCGATCCGGACCGCCACATCGAGCGGGT
CACCGAGCTGCAAGAACTCTTCCTCACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTCGCGGAC
GACGGCGCCGCGGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGCGGTGTTCGCCGAGA
TCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGGCCGCGCAGCAACAGATGGAAGGCCTCCT
GGCGCCGCACCGGCCCAAGGAGCCCGCGTGGTTCCTGGCCACCGTCGGAGTCTCGCCCGACCACCAG
GGCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGCGCCGGGGTGCCCG
CCTTCCTGGAGACCTCCGCGCCCCGCAACCTCCCCTTCTACGAGCGGCTCGGCTTCACCGTCACCGC
CGACGTCGAGGTGCCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGA 
BLASTR 
ATGGCCAAGCCTTTGTCTCAAGAAGAATCCACCCTCATTGAAAGAGCAACGGCTACAATCAACAGCA
TCCCCATCTCTGAAGACTACAGCGTCGCCAGCGCAGCTCTCTCTAGCGACGGCCGCATCTTCACTGG
TGTCAATGTATATCATTTTACTGGGGGACCTTGTGCAGAACTCGTGGTGCTGGGCACTGCTGCTGCT
GCGGCAGCTGGCAACCTGACTTGTATCGTCGCGATCGGAAATGAGAACAGGGGCATCTTGAGCCCCT
GCGGACGGTGCCGACAGGTGCTTCTCGATCTGCATCCTGGGATCAAAGCCATAGTGAAGGACAGTGA
TGGACAGCCGACGGCAGTTGGGATTCGTGAATTGCTGCCCTCTGGTTATGTGTGGGAGGGCTAA 
 
 
Table 10: Sanger sequencing results of RACE clones 
Name Sequence 
5' RACE 
Clone# 
1 
GGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGCTCGTTACTTCTTACAGCTCACAGTCCC
TCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCTTGATTAGTGCAGGGGAAAAGCACTTTAAAA
AGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAAACTGCATCCCAGGTCGGCACAG
ACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
2 
ACAGCTCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTGACCTCTCTCTTGATTAGTGCAGGGG
AAAAGCACTTTAAAAAGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAAACTGCAT
CCCAGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAA
CCCCAGCACCCA 
5' RACE 
Clone# 
3 
AGTGGCGGGGTTCTCGCCGGTCCTGCGGGTCGCTGCTCGGCTGTGGGTTAGCAGCACCCTGAGCGGA
GCGGAAGAGCTGCCCGCCGCCGCGTAACCCCGAGGCCGAGACTCCTGGCCTGGCCTCCTTGGGCCCA
CGACGCCTGCCCCGCGGAGCGGACCCATGGGCCTGAGGTCGGCACAGACGCAACCCAGTCTCCTCCC
ACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
4 
AGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGCTCGTTACTTCTTACAGC
TCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCTTGATTAGTGCAGGGGAAAAG
CACTTTAAAAAGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAAACTGCATCCCAG
GTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCA
GCACCCA 
85 
 
Table 10: Sanger sequencing results of RACE clones 
Name Sequence 
5' RACE 
Clone# 
5 
GGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGCTCGTTACTTCTTACAGCTCACAGTCCC
TCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCTTGATTAGTGCAGGGGAAAAACACTTTAAAA
AGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAAACTGCATCCCAGGTCGGCACAG
ACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCC 
5' RACE 
Clone# 
6 
AGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGCTCGTTACTTCTTACAGC
TCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCCTGATTAGTGCAGGGGAAAAG
CACTTTAAAAAGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAAACTGCATCCCAG
GTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCA
GCACCCA 
5' RACE 
Clone# 
7 
AGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGCTCGTTACTTCTTACAGC
TCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCTTGATTAGTGCAGGGGAAAAG
CACTTTAAAAAGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAAACTGCATCCCAG
GTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCA
GCACCCA 
5' RACE 
Clone# 
8 
CCCAACAAGCCTTGCACCACGAGGAAGTGGCAGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGT
GAAGTTCAAGGGGCTCGTTACTTCTTACAGCTCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCT
GACCTCCCTCTTGATTAGTGCAGGGGAAAAGCACTTTAAAAAGCTGTGTCATGCGTAACTTGCACAT
CTTCTGATTCTGACCTGAAACTGCATCCCAGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCC
GAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
9 
GGGAGACCGAGTAATAATAAAACCCCAGTCTCCCACACAGCTAGCTCTGCGTGAATTACCTTTTCTC
TGTTGCAAATGCCCTTTCTCGATAAATTGGCTGTCTAGGTAACAGGGAAGGTGAACCCACTGGGCAG
TTACACTTTTATCCACCCTTCCAGCTGGATCACGCGCCCTCTTCAATGACATGACACGCAGCTAGAG
TGTATGAGCTTGCTGCCGGCACCTTCCGTCCTGGATCGCATAGCAAGGCCTCAATGGACAGCCAGGT
CGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGC
ACCCA 
5' RACE 
Clone# 
10 
AGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGCTCGTTACTTCTTACAGC
TCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCTTGATTAGTGCAGGGGAAAAG
CACTTTAAAAAGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAAACTGCATCCCAG
GTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCA
GCACCCA 
5' RACE 
Clone# 
11 
AGTGTTTGCCCTGGCTTGTAGCCCAGCGGGGGCTCCGTCATCCCCTGGGGAATGCCTCGGCCTGCAA
GACCGCATACCGCATTGGAACAGGGAAACCACCTACTTCAGCACCTCCCTCAGCAAGGTGGCAGGTC
CCAACAAGCCTTGCACCACGAGGAAGTGGCAGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGTG
AAGTTCAAGGGGCTCGTTACTTCTTACAGCTCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTG
ACCTCCCTCTTGATTAGTGCAGGGGAAAAGCACCTTAAAAAGCTGTGTCATGCGTAACTTGCACATC
TTCTGATTCTGACCTGAAACTGCATCCCAGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCTG
AGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
12 
ATTGGAACAGGGAAACCACCTACTTCAGCACCTCCCTCAGCAAGGTGGCAGGTCCCAACAAGCCTTG
CACCACGAGGAAGTGGCAGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGC
TCGTTACTTCTTACAGCTCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCTTGA
TTAGTGCAGGGGAAAAGCACTTTAAAAAGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGAC
CTGAAACTGCATCCCAGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTC
CTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
13 
CTCGCCGGTCCTGCGGGTCGCTGCTCGGCTGTGGGTTAGCAGCACCCTGAGCGGAGCGGAAGAGCTG
CCCGCCGCCGCGTAACCCCGAGGCCGAGACTCCTGGCCTGGCCTCCTTGGGCCCACGACGCCTGCCC
CGCGGAGCGGACCCATGGGCCTGAGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGT
GCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
14 
GACCGAGTAATAATAAAACTCCAGTCTCCCACACAGCTAGCTCTGCGTGAATTACCTTTTCTCTGTT
GCAAATGCCCTTTCTTGATAAATTGGCTGTCTAGGTAACAGGGAAGGTGAACCCACTGGGCAGTTAC
ACTTTTATCCACCCTTCCAGCTGGATCACGCGCCCTCTTCAATGACATGACACGCAGCTAGAGTGTA
TGAGCTTGCTGCCGGCACCTTCCGTCCTGGATCGCATAGCAAGGCCTCAATGGACAGCCAGGTGCCT
GGTCCGGTCCCACTTTTTTTTCTGTCCTGTTCTCGTTTCCTCTTTGCTTGGCCAAAGAGGGTTGGGC
CAGGGTCCTGAGTGCAAGGGCTTGGCTTGGTGAATTAAAGTGGCAGTAGCCGTGTGGCAGAGAAAAT
TTGTAGATGGGTGAAATCCTGGGCCTACACAGTGACAAAGTGTATATAGACAGCCAGCCTAGTAGGT
GGATGTGACAACCCCAGACTCTTCTAGATTTGTGGATCCGTGCACCTGCCAGACCTGTCTCTGAGCC
ATCTGGGGAGGCTGGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCT
GAATGGAGAACCCCAGCACCCA 
5' RACE GGGAGACCGAGTAATAATAAAACTCCAGTCTCCCACACAGCTAGCTCTGCGTGAATTACCCTTTCTC
86 
 
Table 10: Sanger sequencing results of RACE clones 
Name Sequence 
Clone# 
15 
TGTTGCAAATGCCCTTTCTTGATAAATTGGCTGTCTAGGTAACAGGGAAGGTGGACCCACTGGGCAG
TTACACTTTTATCCACCCTTCCAGCTGGATCACGCGCCCTCTTCAATGACATGACACGCAGCTAGAG
TGTATGAGCTTGCTGCCGGCACCTTCCGTCCTGGATCGCATAGCAAGGCCTCAATGGACAGCCAGGT
GCCTGGTCCGGTCCCACTTTTTTTTCTGTCCTGTTCTCGTTTCCTCTTTGCTTGGCCAAAGAGGGTT
GGGCCAGGGTCCTGAGTGCAAGGGCTTGGCTTGGTGAATTAAAGTGGCAGTAGCCGTGTGGCAGAGA
AAATTTGTAGATGGGTGAAATCCTGGGCCTACACAGTGACAAAGTGTATATAGACAGCCAGCCTAGT
TGGTGGATGTGACAACCCCAGACTCTTCTAGATTTGTGGATCCGTGCACCTGCCAGACCTGTCTCTG
AGCCATCTGGGGAGGCTGGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTG
TCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
16 
GCGGGTCGCTGCTCGGCTGTGGGTTAGCAGCACCCTGAGCGGAGCGGAAGAGCTGCCCGCCGCCGCG
TAACCCCGAGGCCGAGACTCCTGGCCTGGCCTCCTTGGGCCCACGACGCCTGCCCCGCGGAGCGGAC
CCATGGGCCTGAGGTTTGTGTGCGGGGCCTCAGGCGAGCGCTGGCGCAGCCTGTCCCCCATCGTCTG
CGCCCTGCGGGCCTGGCCCTCCCCGTGGAAGGACCGCGGGCTTCGGGGCCCCACGCTGGGGGGCTGA
CTCCTGCTACACACACAGCGGTGGCCGCGGGCCTGGGGCGGCAGCACAGCCATTCTGCTCGGGCTGC
GTGAGCTGACCCCGCTCTCTGTGCACCTACTTTTGCTGCGTTTGGTGCTGAGCCTGAAGTCCCAGGA
CAGGCGGCTGAGGGGGAAAGATGGTGTGAATTGGGTGGGCAGAGACAACTGAAAGCCACAGGACCCG
GTTGGCACCTTTTTGGCCGCCTGCGCCTTTGCCTGCAGCCCCGCTCCCTGGGTCACCCGAAGGAGGA
GCTGGCGCTCTTTCCGGGCGCAGAAGCACCCGACCCACGCTGGAGGAAACGGTCCCTCTGGGCAGGA
GAAGCTTTGGGCCTGGCTGGAGCACACTCACGGAACCACGCCAACGCCTGGCCTGTAGCCAGCTCCC
ACCTCCCCTCCCACCTTCTAAAATGCTTGCGGATCTCACGTGGCCGACCCTAACCAGATACACATGG
GGAAAGGAATCAGGTGGCACACATGCCGCCTTTACTCCATAGAGAACTTCCAATTGTGGGTCGGCAC
AGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
17 
GTGGGTTAGCAGCACCCTGAGCGGAGCGGAAGAGCTGCCCGCCGCCGCGTAACCCCGAGGCCGAGAC
TCCTGGCCTGGCCTCCTTGGGCCCACGACGCCTGCCCCGCGGAGCGGACCCATGGGCCTGAGGTTTG
TGTGCGGGGCCTCAGGCGAGCGCTGGCGCAGCCTGTCCCCCATCGTCTGCGCCCTGCGGGCCTGGCC
CTCCCCGTGGAAGGACCGCGGGCTTCGGGGCCCCACGCTGGGGGGCTGACTCCTGCCACACACACAG
CGGTGGCCGCGGGCCTGGGGCGGCAGCACAGCCATTCTGCTCGGGCTGCGTGAGCTGACCCCGCTCT
CTGTGCACCTACTTTTGCTGCGTTTGGTGCTGAGCCTGAAGTCCCAGGACAGGCGGCTGAGGGGGAA
AGATGGTGTGAATTGGGTGGGCAGAGACAACTGAAAGCCACAGGACCCGGTTGGCACCTTTTTGGCC
GCCTGCGCCTTTGCCTGCAGCCCCGCTCCCTGGGTCACCCGAAGGAGGAGCTGGCGCTCTTTCCGGG
CGCAGAAGCACCCGACCCACGCTGGAGGAAACGGTCCCTCTGGGCAGGAGAAGCTTTGGGCCTGGCT
GGAGCACACTCACGGAACCACGCCAACGCCTGGCCTGTAGCCAGCTCCCACCTCCCCTCCCACCTTC
TAAAATGCTTGCGGATCTCACGTGGCCGACCCTAACCAGATACACATGGGGAAAGGAATCAGGTGGC
ACACATACCGCCTTTACTCCATAGAGAACTTCCAATCGTGGGTCGGCACAGACGCAACCCAGTCTCC
TCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
18 
CCTGCGGGTCGCTGCTCGGCTGTGGGTTGGCAGCACCCTGAGCGGAGCGGAAGAGCTGCCCGCCGCC
GCGTAACCCCGAGGCCGAGACTCCTGGCCTGGCCTCCTTGGGCCCACGACGCCTGCCCCGCGGAGCG
GACCCATGGGCCTGAGGTTTGTGTGCGGGGCCTCAGGCGAGCGCTGGCGCAGCCTGTCCCCCATCGT
CTGCGCCCTGCGGGCCTGGCCCTCCCCGTGGAAGGACCGCGGGCTTCGGGGCCCCACGCTGGGGGGC
TGACTCCTGTCACACACACAGCGGTGGCCGCGGGCCTGGGGCGGTAGCACAGCCATTCTGCTCGGGC
TGCGTGAGCTGACCCCGCTCTCTGTGCACCTACTTTTGCTGCGTTTGGTGCTGAGCCTGAAGTCCCA
GGACAGGCGGCTGAGGGGGAAAGATGGTGTGAATTGGGTGGGCAGAGACAACTGAAAGCCACAGGAC
CCGGTTGGCACCTTTTTGGCCGCCTGCGCCTTTGCCTGCAGCCCCGCTCCCTGGGTCACCCGAAGGA
GGAGCCGGCGCTCTTTCCGGGCGCAGAAGCACCCGACCCACGCTGGAGGAAACGGTCCCTCTGGGCA
GGAGAAGCTTTGGGCCTGGCTGGAGCACACTCACGGAACCACGCCAACGCCTGGCCTGTAGCCAGCT
CCCACCTCCCCTCCCACCTTCTAAAATGCTTGCGGATCTCACGTGGCCGACCCTAACCAGATACACA
TGGGGAAAGGAATCAGGTGGCACACATACCGCCTTTACTCCATAGAGAACTTCCAATTGTGGGTCGG
CACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACC
CA 
5' RACE 
Clone# 
19 
CTCTTCCGGCCGGAGTCAGTGGCGGGGTTCTCGCCGGTCCTGCGGGTCGCTGCTTGGCTGTGGGTTA
GCAGCACCCTGAGCGGAGCGGAAGAGCTGCCCGCCGCCGCGTAACCCCGAGGCCGAGACTCCTGGCC
TGGCCTCCTTGGGCCCACGACGCCTGCCCCGCGGAGCGGACCCATGGGCCTGAGGTTTGTGTGCGGG
GCCTCAGGCGAGCGCTGGCGCAGCCTGTCCCCCATCGTCTGCGCCCTGCGGGCCTGGCCCTCCCCGT
GGAAGGACCGCGGGCTTCGGGGCCCCACGCTGGGGGGCTGACTCCTGCCACACACACAGCGGTGGCC
GCGGGCCTGGGGCGGCAGCACAGCCATTCTGCTCGGGCTGCGTGAGCTGACCCCGCTCTCTGTGCAC
CTACTTTTGCTGCGTTTGGTGCTGAGCCTGAAGTCCCAGGACAGGCGGCTGAGGGGGAAAGATGGTG
TGAATTGGGTGGGCAGAGACAACTGAAAGCCACAGGACCCGGTTGGCACCTTTTTGGCCGCCTGCGC
CTTTGCCTGCAGCCCCGCTCCCTGGGTCACCCGAAGGAGGAGCTGGCGCTCTTTCCGGGCGCAGAAG
87 
 
Table 10: Sanger sequencing results of RACE clones 
Name Sequence 
CACCCGACCCACGCTGGAGGAAACGGTCCCTCTGGGCAGGAGAAGCTTTGGGCCTGGCTGGAGCACA
CTCACGGAACCACGCCAACGCCTGGCCTGTAGCCAGCTCCCACCTCCCCTCCCACCTTCTAAAATGC
TTGCGGATCTCACGTGGCCGACCCTAACCAGATACACATGGGGAAAGGAATCAGGTGGCACACATAC
CGCCTTTACTCCATAGAGAACTTCCAATTGTGGGTAAGAACAAAGCCCCACCTCTTCCTAATAGATG
CAGTTTTCCACCTGCAGCCAAAAAGACAACCTGTTATTAGCTTTTTTCCCAGAGGACAGGCATCTCT
ATGAAACTGCCATTGCAAAATTTGCCGACAGTGAGATAACCAGCTCCATTTTGCTTCTAACCTCCAT
GCCCTCCTTGTTTACTGCTGCACGCAGGTTGAACTGTGGGAGGAACTTAGTTTAAAACAAAGATGAT
AACAGCCCTTTCCCAAAGGAAACCTTTCCTGGGGATTAGCCTGCTTTTGTGGGACCAACAGATTAGC
CACAAGATTAGAAACTACGGTTGAAGAGTCACGCAGCGGGAGGCTACAGGATTCTGACCCTCCCCAA
ACTGCTCCTGGCGATAACATCACCATCGTAAAGCCTAAGATCAGCACTTGGTGGGTCACCTGGCACC
ACCCAGGCTCATCTGATGTTGTGGCACCCAGGAACTGACTCAGTGCGAAAACAGCTTCGACTCCCTG
TGATTTCATCTCTGACCTGACCAATGGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGA
GTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
20 
CCTGCGGGTCGCTGCTTGGCTGTGGGTTAGCAGCACCCTGAGCGGAGCGGAAGAGCTGCCCGCCGCC
GCGTAACCCCGAGGCCGAGACTCCTGGCCTGGCCTCCTTGGGCCCACGACGCCTGCCCCGCGGAGCG
GACCCATGGGCCTGAGGTTTGTGTGCGGGGCCTCAGGCGAGCGCTGGCGCAGCCTGTCCCCCATCGT
CTGCGCCCTGCGGGCCTGGCCCTCCCCGTGGAAGGACCGCGGGCTTCGGGGCCCCACGCTGGGGGGC
TGACTCCTGCCACACACACAGCGGTGGCCGCGGGCCTGGGGCGGCAGCACAGCCATTCTGCTCGGGC
TGCGTGAGCTGACCCCGCTCTCTGTGCACCTACTTTTGCTGCGTTTGGTGCTGAGCCTGAAGTCCCA
GGACAGGCGGCTGAGGGGGAAAGATGGTGTGAATTGGGTGGGCAGAGACAACTGAAAGCCACAGGAC
CCGGTTGGCACCTTTTTGGCCGCCTGCGCCTTTGCCTGCAGCCCCGCTCCCTGGGTCACCCGAAGGA
GGAGCTGGCGCTCTTTCCGGGCGCAGAAGCACCCGACCCACGCTGGAGGAAACGGTCCCTCTGGGCA
GGAGAAGCTTTGGGCCTGGCTGGAGCACACTCACGGAACCACGCCAACGCCTGGCCTGTAGCCAGCT
CCCACCTCCCCTCCCACCTTCTAAAATGCTTGCGGATCTCACGTGGCCGACCCTAACCAGATACACA
TGGGGAAAGGAATCAGGTGGCACACATACCGCCTTTACTCCATAGAGAACTTCCAATTGTGGGTAAG
AACAAAGCCCCACCTCTTCCTAATAGATGCAGTTTTCCACCTGCAGCCAAAAAGACAACCTGTTATT
AGCTTTTTTCCCAGAGGACAGGCATCTCTATGAAACTGCCATTGCAAAATTTGCCGACAGTGAGATA
ACCAGCTCCATTTTGCTTCTAACCTCCATGCCCTCCTTGTTTACTGCTGCACGCAGGTTGAACTGTG
GGAGGAACTTAGTTTAAAACAAAGATGATAACAGCCCTTTCCCAAAGGAAACCTTTCCTGGGGATTA
GCCTGCTTTTGTGGGACCAACAGATTAGCCACAAGATTAGAAACTACGGTTGAAGAGTCACGCAGCG
GGAGGCTACAGGATTCTGACCCTCCCCAAACTGCTCCTGGCGATAACATCACCATCGTAAAGCCTAA
GATCAGCACTTGGTGGGTCACCTGGCACCACCCAGGCTCATCTGATGTTGTGGCACCCAGGAACTGA
CTCAGTGCGAAAACAGCTTCGACTCCCTGTGATTTCATCTCTGACCTGACCAATGGTCGGCACAGAC
GCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
21 
GAGACCGAGTAATAATAAAACTACAGTCTCCCACACAGCTAGCTCTGCGTGAATTACCTTTTCTCTG
TTGCAAATGCNCTTTCTTGATAAATNNGCTGTCTAGGCAACAGGGAAGGTGAACCCACTGGGCAGTT
ACACTTTTATCCACCCTTCCAGCTGGATCACGCGCCCTCTTCAATGACATGACACGCAGCTAGAGTG
TATGAGCTTGCTGCCGGCACCTTCCGTCCTGGATCGCATAGCAAGGCCTCAATGGACAGCCAGGTGC
CTGGTCCGGTCCCACTNNTTTTTCTGTCCTGTTCTCGTTTCCTCTTTGCTTGGCCAAAGAGGNTTGG
GCCAGGGTCCTGAGTGCAAGGGCTTGGCTTAGTGAATTAAAGTGGCAGTAGCCGTGTGGCAGAGAAA
ATNNNTAGATGGGTGAAATCCTGGGCCTNCACAGTGACAAAGTGTATATAGACAGCCAGCCTAGTTG
GTGGATGTGACAACCCCAGACTCTTCTNGATTTGTGGATCCGTGCACCTGCCAGACCTGTCTCTGNG
CCATCTGGGGAGGNNGGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGNGAGTGCAGTGTC
CTGAATGGAGAACCCCAGCACCC 
5' RACE 
Clone# 
22 
ACAGTGAGATAACCAGCTCCATTTTGCTTCTAACCTCCATGCCCTCCTTGTTTACTGCTGCACGCAG
GTTGAACTGTGGGAGGAACTTAGTTTAAAACAAAGATGATAACAGCCCTTTCCCAAAGGAAACCTTT
CCTGGGGATTAGCCTGCTTTTGTGGGACCAACAGATTAGCCACAAGATTAGAAACTACGGTTGAAGA
GTCACGCAGCGGGAGGCTACAGGATTCTGACCCTCCCCAAACTGCTCCTGGCGATAACATCACCATC
GTAAAGCCTAAGATCAGCACTTGGTGGGTCACCTGGCACCACCCAGGCTCATCTGATGTTGTGGCAC
CCAGGAACTGACTCAGTGCGAAAACAGCTTCGACTCCCTGTGATTTCATCTCTGACCTGACCAATGG
GTACTTCTGACTCACTGGCTGCCCCCCACCCACCAGCTTATCTTTAAAAACTCCAAACCCCAGATGC
TCAGGGAGACCGAGTAATAATAAAACTCCAGTCTCCCACACAGCTAGCTCTGCGTGAATTACCTTTT
CTCTGTTGCAAATGCCCTTTCTTGATAAATTGGCTGTCTAGGTAACAGGGAAGGTGAACCCACTGGG
CAGTTACACTTTTATCCACCCTTCCAGCTGGATCACGCGCCCTCTTCAATGACATGACACGCAGCTA
GAGTGTATGAGCTTGCTGCCGGCACCTTCCGTCCTGGATCGCATAGCAAGGCCTCAATGGACAGCCA
GGTGCCTGGTCCGGTCCCACTTTTTTTTCTGTCCTGTTCTCGTTTCCTCTTTGCTTGGCCAAAGAGG
GTTGGGCCAGGGTCCTGAGTGCAAAGGCTTGGCTTGGTGAATTAAAGTGGCAGTAGCCGTGTGGCAG
AGAAAATTTGTAGATGGGTGAAATCCTGGGCCTACACAGTGACAAAGTGTATATAGACAGCCAGCCT
88 
 
Table 10: Sanger sequencing results of RACE clones 
Name Sequence 
AGTTGGTGGATGTGACAACCCCAGACTCTTCTAGATTTGTGGATCCGTGCACCTGCCAGACCTGTCT
CTGAGCCATCTGGGGAGGCTGGGTAAGATTTCCCCCGTCAGGGCCTGAGCCTCATCTCCAAGCTGCT
GGCTTCAGCCCAGCTGCCACCAGCGCTGTCTCTGTCTTGCGCTTTCCAGAGAGAGACTGACTCATTT
TGAGCTCCAGGCCTACCAGGCAGCCCAACCGCGGCAGTAACTGCCTCTCACACTGAGGATGGCTCAT
GCTCTGGTCCAGCCATGGCTTGAACACCTCCCAACAAGAACAAAGCCAGACTCATTCTCCCTAGCAT
CTTCTTCCTTGCTCAAAGATCCCACACCCCGTTAGAAGCTGGAACTGGGTCCTTGTCACCTTCCTCA
CCTCCCCAGTCGTAGTCTGGTTAATCCTTACATCTCACCACGGTCACCGTGGCTAGATGTGACCTCC
GCGATGCTTCAGGCACGTACCAGGGCAGCCTGGGCAGGGCTGGTCACTGTGATCTCATGAGGTGTGA
ACTTGACCCCGGCCTTCTTTCCTGGGATGCCGGCTAAGGACACAAGTTCAGTGTTTGCCCTGGCTTG
TAGCCCAGCGGGGGCTCCGTCATCCCCTGGGGAATGCCTCGGCCTGCAAGACCGCATACCGCATTGG
AACAGGGAAACCACCTACTTCAGCACCTCCCTCAGCAAGGTGGCAGGTCCCAACAAGCCTTGCACCA
CGAGGAAGTGGCAGTGGCATTCGGGATATGGCTCCCTGGCCAGCTTGTGAAGTTCAAGGGGCTCGTT
ACTTCTTACAGCTCACAGTCCCTCCCGGGTCCAGCACACCTGAGGGCTGACCTCCCTCTTGATTAGT
GCAGGGGAAAAGCACTTTAAAAAGCTGTGTCATGCGTAACTTGCACATCTTCTGATTCTGACCTGAA
ACTGCATCCCAGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAA
TGGAGAACCCCAGCACCCA 
5' RACE 
Clone# 
23 
AGGGAGACCGAGTAATAATAAAACTCCAGTCTCCCACACAGCTAGCTCTGCGTGAATTACCTTTTCT
CTGTTGCAAATGCCCTTTCTTGATAAATTGGCTGTCTAGGTAACAGGGAAGGTGAACCCACTGGGCA
GTTACACTTTTATCCACCCTTCCAGCTGGATCACGCGCCCTCTTCAATGACATGACACGCAGCTAGA
GTGTATGAGCTTGCTGCCGGCACCTTCCGTCCTGGATCGCATAGCAAGGCCTCAATGGACAGCCAGG
TGCCTGGTCCGGTCCCACTTTTTTTTCTGTCCTGTTCTCGTTTCCTCTTTGCTTGGCCAAAGAGGGT
TGGGCCAGGGTCCTGAGTGCAAGGGCTTGGCTTGGTGAATTAAAGTGGCAGTAGCCGTGTGGCAGAG
AAAATTTGTAGATGGGTGAAATCCTGGGCCTACACAGTGACAAAGTGTATATAGACAGCCAGCCTAG
TTGGTGGATGTGACAACCCCAGACTCTTCTAGATTTGTGGATCCGTGCACCTGCCAGACCTGTCTCT
GAGCCATCTGGGGAGGCTGGGTCGGCACAGACGCAACCCAGTCTCCTCCCACCTCCGAGAGTGCAGT
GTCCTGAATGGAGAACCCCAGCACCCA 
3' RACE 
Clone# 
1 
GTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCAGAAGCATCCACGG
AAGGACTAAATTCTACACATGAAGGCAAACGTCCGTGGTTGACAGAAATTACACTGGCCAGAATCCC
CAGTCCCCATGAGGCTTGTCCAGACGCAGTGAACCAGTCGCAGCTGATAACACACAGACCATTCCCG
ATCCCAGAGGTGCATTTCAGGATTCATTCTATTTCATCAGAGACGGGGTCTTCCCGTGTTGCCCAGG
CTGGTCTCGAACTCCTGGGCTGAAGCAATCTTCCTGCCTTGGCCTCCCAGAGGGTTGGAATTGCAGA
TGTGAGGTGTGTCCTGGAACCCTGGCTGCACCCACAGATACAGCCACTCCTGGGCCCATGTGGATGT
AACCTTCGAGTGCCGGAATGCCTCGTCTCCATGGAGACCAAACTCAAGGGCCTGACTGGCCCAGTCT
ACCGAGACCATGAGACCTGCTGTGCCCCTCGGCCAGGCCAACCCAAATTCTTTTAAATAAAAGGCAC
AAGCCACAGCCA 
3' RACE 
Clone# 
2 
GTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCAGAAGCATCCACTG
AAGGACTAAATTCTACACATGAAGGCAAACGTCCGTGGTTGACAGAAATTACACTGGCCAGAATCCC
CAGTCCCCATGAGGCTTGTCCAGACGCAGTGAACCAGTCGCAGCTGATAACACACAGACCATTCCCG
ATCCCAGAGGTGCATTTCAGGATTCATTCTATTTCATCAGAGACGGGGTCTTCCTGTGTTGCCCAGG
CTGGTCTCGAACTCCTGGGCTGAAGCAATCTTCCTGCCTTGGCCTCCCAGAGGGTTGGAATTGCAGA
TGTGAGGTGTGTCCTGGAACCCTGGCTGCACCCACAGATACAGCCACTCCTGGGCCCATGTGGATGT
AACCTTCGAGTGCCGGAATGCCTCGTCTCCATGGAGACCAAACTCAAGGGCCTGACTGGCCCAGTCT
ACCGAGACCATGAGACCTGCTGTGCCCCTCGGCCAGGCCAACCCAAATTCTTTTAAATAAAAGGCAC
AAGCCACAGCCACACCAGC 
3' RACE 
Clone# 
3 
GTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCAGAAGCATCCACTG
AAGGACTAAATTCTACACATGAAGGCAAACGTCCGTGGTTGACAGAAATTACACTGGCCAGAATCCC
CAGTCCCCACGAGGCTTGTCCAGACGCAGTGAACCAGTCGCAGCTGATAACACACAGACCATTCCCG
ATCCCAGAGGTGCATTTCAGGATTCATTCTATTTCATCAGAGACGGGGTCTTCCTGTGTTGCCCAGG
CTGGTCTCGAACTCCTGGGCTGAAGCAATCTTCCTGCCTTGGCCTCCCAGAGGGTTGGAATTGCAGA
TGTGAGGTGTGTCCTGGAACCCTGGCTGCACCCACAGATACAGCCACTCCTGGGCCCATGTGGATGT
AACCTTCGAGTGCCGGAATGCCTCGTCTCCATGGAGACCAAACTCAAGGGCCTGACTGGCCCAGACT
ACCGAGACCATGAGACCTGCTGTGCCCCTCGGCCAGGCCAACCCAAATTCTTTTAAATAAAAGGCAC
AAGCCACAGC 
3' RACE 
Clone# 
4 
GTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCAGAAGCATCCACTG
AAGGACTAAATTCTACACATGAAGGCAAACGTCCGTGGTTGACAGAAATTACACTGGCCAGAATCCC
CAGTCCCCATGAGGCTTGTCCAGACGCAGTGAACCAGTCGCAGCTGATAACACACAGACCATTCCCG
ATCCCAGAGGTGCATTTCAGGATTCATTCTATTTCATCAGAGACGGGGTCTTCCTGTGTTGCCCAGG
CTGGTCTCGAACTCCTGGGCTGAAGCAATCTTCCTGCCTTGGCCTCCCAGAGGGTTGGAATTGCAGA
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Table 10: Sanger sequencing results of RACE clones 
Name Sequence 
TGTGAGGTGTGTCCTGGAACCCTGGCTGCACCCACAGATACAGCCACTCCTGGGCCCATGTGGATGT
AACCTTCGAGTGCCGGAATGCCTCGTCTCCATGGAGACCAAACTCAAGGGCCTGACTGGCCCAGTCT
ACCGAGACCATGAGACCTGCTGTGCCCCTCGGCCAGGCCAACCCAAATTCTTTTAAATAAAAGGCAC
AAGCCACAGCCACACCAGCAGGAAGTGGATACAGGATAAGGGGCAGGGCTCACATCTCATCCTCATC
AGCCTTTGACCAGGCGACGGAGTCTGTGATAGCTAGCTTATCTGCTCTATGCTCCAGGGACCTGGCC
GGAACGAGCCGAGTTGCTGTCCTCATGGAACTCTCATCCTAGTGGGGCAGAGACAAGGACGGTGTAA
CGTGCCCGGGGGTCAGCACCACAGACAAAACGCAGGGAGCACGGCACAGTGTGGGCCAGGGAAGGCC
TGGCTTCCCAAGGGTGTGGGCGCGAGCAGCATGGCTGTGGGGAGTTCTAGGTGCAGAGAACTACTCC
AGAGACGAAGCCAGGCCTGCGAGGAGGCCGGAGCGCATGAGGGGAAGGCACGAGGCAAGGCTGCCAG
GGCTGTGCTGGTGGTGCGGGACGGTCCTGTGGGGGTAGCTGCGGAGATGGCACTGATGCCTTCGGCT
CCAGCAGCATCCTGGGCTGGTGCGGGCCAATAAGGGGCAGGGTTGGGGCAGGATGAAAGGCACAAGC
CACAGCCATGTCAAGCAGGAAGTGGATGCAGGGTACAGCCTGTCAGGGTCAGGGTGAAAGGCAGGGA
GGCGGGTAGGCCATAGGTGAATTTGGAGCAGCCTGTAGAGGACAGGATGTGCCATCAAAGACTTGTT
CTTGGGTCCAGCTGAGACTGTCCCTTGGGGCTTCCTGTCACCTTGTGCAGGATAGTGAGACCATCCT
TGGAAAACCCATCGGGACTGCAGAGCGCGGCTCAGAGCTGACTGTCCAGGCCTGGCAGGGGCTGACC
CCTGGGCGCTGGTGCACCCTCCGTGCGGCCTCTTGGAGGAAGCACACAAGGCGACAGTTCCCAGCTG
CCGCCTGAGATGCAGCATCTGCTTTACTCCAGCCCAGCACTGCTCACCGTCACTGCCCACTCTTATG
ATTTTACTTCCCTTCATATTTGTGATTTTGCAAAGATGGTGTTGACTTACAGCTGCAGCATCAAATG
ACTGACTGCCACCAGCTTGGCCCCAGCTCAGGGACATGTCTGAGCCCAGGCAGAGCACCCTAGTGGC
CGGGAAGCCTCACCTGGAGCTCCTGCGGGTGGCTGCAGTCCGCCAGGTGATCCGTGAGGAGGGCTTG
GAGAGGCCCCATGATGGCGTGGAAGGATGGCAGGGACCCGTACATGAGCACGCAGCGCTTCAGCAGG
GCCAGGCCCACAGCCAGGCAGGACAGTCTGTGAGGGCAGGAGGCAAGAGGAGGTCCAACTTGTTCTG
TTTGTCACTGACAAAACCAATAACGTGGCAAAAATGAACTTCCCCACTTCCACTAGGCTGAAAACTC
CAGTGTGGCCACCTTGGCCGGCCAGGGTTGGGCCCATGCAACCACGGGCAAGGCAGGCTCAGGGTCA
GGCCTAACGCAGGAGGGGAGGCTGTGGGAACCGCAGCGCCAGCTGGGATGGGGCGGCTCCATTTTTG
GTTCCAAATTATGATTT 
3' RACE 
Clone# 
5 
GTCTCCTCCCACCTCCGAGAGTGCAGTGTCCTGAATGGAGAACCCCAGCACCCAGAAGCATCCACTG
AAGGACTAAATTCTACACATGAAGGCAAACGTCCGTGGTTGACAGAAATTACACTGGCCAGAATCCC
CAGTCCCCATGAGGCTTGTCCAGACGCAGTGAACCAGTCGCAGCTGATAACACACAGACCATTCCCG
ATCCCAGAGGTGCATTTCAGGATTCATTCTATTTCATCAGAGACGGGGTCTTCCTGTGTTGCCCAGG
CTGGTCTCGAACTCCTGGGCTGAAGCAATCTTCCTGCCTTGGCCTCCCAGAGGGTTGGAATTGCAGA
TGTGAGGTGTGTCCTGGAACCCTGGCTGCACCCACAGATACAGCCACTCCTGGGCCCATGTGGATGT
AACCTTCGAGTGCCGGAATGCCTCGTCTCCATGGAGACCAAACTCAAGGGCCTGACTGGCCCAGTCT
ACCGAGACCATGAGACCTGCTGTGCCCCTCGGCCAGGCCAACCCAAATTCTTTTAAATAAAAGGCAC
AAGCCACAGCCACACCAGCAGGAAGTGGATACAGGATAAGGGGCAGGGCTCACATCTCATCCTCATC
AGCCTTTGACCAGGCGACGGAGTCTGTGATAGCTAGCTTATCTGCTCTATGCTCCAGGGACCTGGCC
GGAACGAGCCGAGTTGCTGTCCTCATGGAACTCTCATCCTAGTGGGGCAGAGACAAGGACGGTGTAA
CGTGCCCGGGGGTCAGCACCACAGACAAAACGCAGGGAGCACGGCACAGTGTGGGCCAGGGAAGGCC
TGGCTTCCCAAGGGTGTGGGCGCGAGCAGCATGGCTGTGGGGAGTTCTAGGTGCAGAGAACTACTCC
AGAGACGAAGCCAGGCCTGCGAGGAGGCCGGAGCGCATGAGGGGAAGGCACGAGGCAAGGCTGCCAG
GGCTGTGCTGGTGGTGCGGGACGGTCCTGTGGGGGTAGCTGCGGAGATGGCACTGATGCCTTCGGCT
CCAGCAGCATCCTGGGCTGGTGCGGGCCAATAAGGGGCAGGGTTGGGGCAGGATGAAAGGCACAAGC
CACAGCCATGTCAAGCAGGAAGTGGATGCAGGGTACAGCCTGTCAGGGTCAGGGTGAAAGGCAGGGA
GGCGGGTAGGCCATAGGTGAATTTGGAGCAGCCTGTAGAGGACAGGATGTGCCATCAAAGACTTGTT
CTTGGGTCCAGCTGAGACTGTCCCTTGGGGCTTCCTGTCACCTTGTGCAGGATAGTGAGACCATCCT
TGGAAAACCCATCGGGACTGCAGAGCGCGGCTCAGAGCTGACTGTCCAGGCCTGGCAGGGGCTGACC
CCTGGGCGCTGGTGCACCCTCCGTGCGGCCTCTTGGAGGAAGCACACAAGGCGACAGTTCCCAGCTG
CCGCCTGAGATGCAGCATCTGCTTTACTCCAGCCCAGCACTGCTCACCGTCACTGCCCACTCTTATG
ATTTTACTTCCCTTCATATTTGTGATTTTGCAAAGATGGTGTTGACTTACAGCTGCAGCATCAAATG
ACTGACTGCCACCAGCTTGGCCCCAGCTCAGGGACATGTCTGAGCCCAGGCAGAGCACCCTAGTGGC
CGGGAAGCCTCACCTGGAGCTCCTGCGGGTGGCTGCAGTCCGCCAGGTGATCCGTGAGGAGGGCTTG
GAGAGGCCCCATGATGGCGTGGAAGGATGGCAGGGACCCGTACATGAGCACGCAGCGCTTCAGCAGG
GCCAGGCCCACAGCCAGGCAGGACAGTCTGTGAGGGCAGGAGGCAAGAGGAGGTCCAACTTGTTCTG
TTTGTCACTGACAAAACCAATAACGTGGCAAAAATGAACTTCCCCACTTCCACTAGGCTGAAAACTC
CAGTGTGGCCACCTTGGCCGGCCAGGGTTGGGCCCATGCAACCACGGGCAAGGCAGGCTCAGGGTCA
GGCCTAACGCAGGAGGGGAGGCTGTGGGAACCGCAGCGCCAGCTGGGATGGGGCGGCTCCATTTTTG
GTTCCAAATTATGATTTGTGAAATCAAGCAAATGTATTTTGAAAATGAAAAGAAAAAGGGACAGCAA 
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